Browse Tag

Espionage Act

Clevelanders have aided the Israeli Defense Forces in building an army of 160,000 “friends” in 13 U.S. states, including Ohio, as treasonous traitors quarter and conceal foreign troops on US soil

CLEVELAND, OH – What if illegal aliens and immigrants from Communist China decided to organize a 501.c3 non-profit to support the Peoples Liberation Army and called it the Friends of the Peoples Liberation Army? 

Chapters inside the United States of America would exist with Communist Chinese soldiers recruiting members secretly in uniform and raising money on our soil.  Chinese children would be taught to pledge allegiance to the flag of Communist China and be indoctrinated that their “Red army” is operating inside the United States of America and abroad to protect them and their interests from American racists.  Under the current immigrant-controlled Democratic Party a racist is an American who wants immigration laws obeyed and enforced.

Loyal. law abiding and patriotic Americans would be rightfully alarmed and concerned with a 160,000 presence of Friends of the Peoples Liberation Army operating openly inside the United States of America.  We’d expect the leaders and organizers to be arrested, prosecuted and jailed for treason by our law enforcement agencies if they weren’t infiltrated and obstructed with “sanctuary city” foolishness.

The Central Intelligence Agency has described Israel as the #1 espionage threat to the United States of America. It also seems rather insane for the United States Congress to arm Russians, Polish and Ukrainians who took over Palestine; and who have consistently attacked U.S. interests and citizens. Retired Israeli Defense Forces Major General Meir Klifi-Amir built an army of 160,000 Friends of the Israeli Defense Forces inside the United States of America in violation of espionage and foreign agents registration laws. IDF soldiers were also infiltrated into the United States of America. Among the IDF friends are elected officials, judges, prosecutors, law enforcement officers, business owners and actors. It explains why the non-profit has not been criminally investigated.

This “friends” of a foreign military scheme is exactly what Russian, Polish and Ukrainian Jews are operating inside the United States of America under a non-profit called the Friends of the Israeli Defense Forces (FIDF) headquartered in New York.  Until September 2020 the national FIDF in New York was led by a retired Israeli Defense Forces (IDF) major general named of Meir Klifi Amir who once commanded the Middle East nation’s ground forces.  This Israeli citizen’s equivalent today is Major General Yaacov Barak who sent soldiers into a Palestinian mosque and is coordinating the evictions and ethnic cleansing now taking place in Palestine’s Gaza.

Klifi-Amir’s IDF ground forces command appears to coincide with Operation Hot Winter and Operation Cast Lead in 2008. The Palestinian body count between the two “missions” was 1500 as the IDF operates like the best armed and most violent eviction bailiffs on the planet.

The heavily-armed house-to-house searchers are vital to Israel’s “innovative” economic development strategies.  Instead of building new homes the Israeli government steals them from forcibly unarmed Palestinians and then labels the displaced homeowners “terrorists” for complaining.

Under a “Jewish state” only Jews have rights and access to the courts.  According to a website called Yesh Din, 91 percent of complaints Palestinians make about IDF ideological abuses are uninvestigated by the Israeli government.  Israel sounds like Cleveland and Cuyahoga County in the Northern District of Ohio under pro-police city, state and federal prosecutors.  The semitic Palestinians are the equivalent to semitic Christian American Negroes, poor White Anglo Saxon Protestants and Catholic Puerto Ricans in Cleveland.  Christianity and Islam are semitic religions.

Ward 14 councilwoman Jasmine Santana and Ward 6’s Blaine Griffin traveled to Israel as guests of the Cleveland Jewish Federation.  Santana was so impressed she wanted to implement Israel’s “innovative” economic development strategies in Cleveland.  She’s expected to be defeated in 2021 by former Councilman Nelson Cintron.

In Cuyahoga County, Ohio and 12 other states across the United States of America, Russian, Polish and Ukrainian Jews have organized FIDF chapters with a combined membership of 160,000.  Annually each chapter has been hosting fundraisers since 1981 to raise money to fund “settlers” relocating from the United States of America to Palestine; and providing supportive services to IDF combat soldiers involved in violently evicting Palestinians to give their homes to “Jewish” settlers with Brooklyn accents.

Israel’s latest attack on the Gaza strip in Palestine and neighborhoods like Sheikh Jarrah can be attributed in part to Russian, Ukrainian and Polish New York Jewish settlers to Israel who needed a place to live.  A portion of the money raised for the FIDF is spent on encouraging Russian, Polish and Ukrainian Jews to leave the United States of America for Palestine under the government of Israel’s armed control.  The FIDF’s donors don’t appear to have the same loyalty to or interest in caring for U.S. soldiers, veterans and our families.

Klifi-Amir is an Israeli citizen and foreign government official, and there are no immigration laws giving Russian, Polish or Ukrainian Jews from Israel automatic dual citizenship.  Like every other alien seeking admission into the United States of America under a visa, Klifi-Amir was required by this nation’s immigration laws to apply through the U. S. Department of State.

The Israeli was required to be vetted for his involvement in terrorist organizations and a determination had to be made to see if his skills were useful to this nation with the U.S. Department of Labor.  The board of the non-profit FIDF, according to federal immigration laws, was required to submit an I-9 to the U.S. Department of Labor to see if the Israeli alien retired IDF general they hired was eligible to work in the United States of America.

Foreign soldiers sneaking into the United States of America to recruit “friends” and raise money violates espionage, immigration and treason laws. The idea that American citizens would raise money to support foreign soldiers and not raise money to support members and veterans of the United States armed forces seems rather traitorous.

Klifi-Amir was paid over $1 million annually to infiltrate uniformed IDF soldiers into the United States of America through the organization’s 13 “friends” chapters; and to lobby for the government of Israel which he did as an unregistered foreign agent.  Between 2014 and 2020 he led the organization to raise over $535 million from wealthy Russian, Polish, Ukrainian, Syrian and Turkish Jews and friends inside the United States of America.  The agent of a foreign government even led the organization to apply for and receive a payroll protection loan to aid its efforts in supporting foreign troops.  Hollywood kicked in big time with $36 million raised at one event.

Among the FIDF’s hollywood supporters are Sylvester Stallone, Arnold Schwarzenegger, Chris Tucker, Lionel Richie, Pamela Anderson Lee and Jason Alexander.  Stallone’s mother, Jacqueline Labofish, was a Russian Jew.  Anderson’s relatives on her mother’s side of the family are Russian Jews.  Her father’s ancestors are Romani Jews.  Schwarzenegger is apologetic and supportive of Israel because his father was an Austrian Nazi.

Klifi-Amir counts among his successes the $40 billion in aid promised to Israel for 10 years by a Republican-controlled Congress under Donald Trump as president.  There is no record of either the FIDF or Klifi Amir being registered with the the United States Department of Justice pursuant to the Foreign Agents Registration Act as agents of the Israeli government.

Israel’s military infiltrator appears to have ignored espionage as well as immigration laws during his six-years of building a 160,000 command of Jews in America who have pledged allegiance to Israel and harbored uniformed members of the foreign government’s armed forces on U.S. soil.  When Stingray cell phone tower emulators were found to have been installed near the White House by Israeli agents Trump said “no big deal.”   A settlement for Jews that bears his name is already cleared.  Trump Heights.  The FBI and U.S. Department of Justice under his command turned a blind eye to the IDF’s recruitment and fundraising on U.S. soil.

These “American” children were not pledging allegiance to the United States of America at the Joseph and Florence Mandel Jewish Day School in Beachwood, Ohio in 2015 when they were visited by IDF soldiers.

Russians, Polish and Ukrainian Jews living in America and claiming citizenship have no special privileges to ignore the nation’s espionage laws in their interactions with Israeli, Russian, Polish and Ukrainian government officials on behalf of those governments.  Sister City agreements without U.S. Department of State oversight are not lawful.   The Logan Act used to prosecute Trump’s campaign team still prevents Americans from initiating any correspondence with the officials of foreign governments.  IDF soldiers and their “IDF for life” retirees are a foreign government’s agents.

In Ohio it’s up to the two U.S. Attorneys for the northern and southern districts of the state to enforce espionage and treasons laws … locally.  During the administration of Barack Obama in his official capacity as President, the Democrat assigned attorney Steve Dettelbach to protect northern Ohioans from foreign spies and spying.  Dettelbach, a Russian American, had conflicts of interest.

Uniformed members of the Israeli Defense Forces (IDF) are shown above in a video Karil Bialostosky-Dettelbach uploaded on October 15 2015 to her YouTube page that features the foreign soldiers interacting with children, faculty and parents at the Joseph and Florence Mandel Jewish Day School in Beachwood, Ohio.  Joseph Mandel was Josh Mandel’s grandfather and a founder of Premier Industrial.  He died on March 22, 2016. Steven Dettelbach in 2015 was serving as Obama’s U.S. Attorney when his Russian-born Mexican immigrant wife was promoting the IDF.

Karil Bialostosky was born in Mexico City to Russian immigrants Saul and the late Dinorah Bialostosky in January of 1969.  Dinorah was born on August 5, 1940 or 16 days before Leon Trotsky was assassinated in Mexico City on August 21, 1940 .  Trotsky who’s real name was Lev Bronstein fled to Mexico after being kicked out of Russia by Josef Stalin.  Stalin didn’t trust the Marxist so he made sure “the Red was dead.”

Saul or Samuel Bialostosky (Bialostozky’s) date of birth identifies him as being born in Lapy, Poland on February 6, 1937.  He’s 84 years old today.  Karil Bialostosky and Dettelbach married on September 23, 2000 in Manassas, Virginia.  She claims to have been naturalized as a U.S. citizen in 1989 at the age of 20 instead of 16.

Former US Attorney for the Northern District of Ohio Steve Dettelbach’s Mexican immigrant wife, Karil Bialostosky, worked for both the administrations of Jane Campbell and Frank Jackson. He said Campbell’s administration, with Jackson as council president, did nothing with the federal government’s first two investigations when he led the third. But instead of investigating the 600 incident reports of known cop crimes criminally, Dettelbach’s investigation was civil.  Numerous Russian, Ukrainian and Polish men and women are employed as Cleveland police in a city with an American Negro majority.

Karil was 14 when her parents brought their family (she has a sister named Lara) to the United States of America from Mexico City in 1979 for what Dinorah claimed were “business purposes.”  That’s what Dinorah told the Brownsville Herald when she worked as an interpreter for Cameron county’s courts and Saul was a partner in a gift shop.

Her job skills as a freelance interpreter in Mexico City and “business purposes” reasons for requesting a visa would not have authorized either Saul or Dinorah to be admitted into the United States of America for employment or business under immigration laws in existence in 1979.  They weren’t the “Einstein’s” American immigration laws favored and Russians, Polish and Ukrainians had been excluded with the Chinese in the Chinese Exclusion Acts of the 1890’s.

By 1973 the number of “legally admitted” Russians living in the United States of America numbered fewer than 1300 according to the New York Times.  There’s no way 6 million Russians are in the United States of America legally today with close to 40 serving in Congress.

Dettelbach’s wife worked for the mayoral administrations of Jane Campbell and Jackson while U.S. Department of Justice officials were investigating their management of unconstitutional policing.  In 2006 she joined Chinese attorney Margaret Wong’s challenge to requirements that aliens and immigrants prove their citizenship before voting.  In their losing case against Secretary of State J. Kenneth Blackwell, Wong and Bialostosky argued that natural born Americans didn’t have to prove our citizenship.

Within months after arriving in Brownsville, Texas from Mexico City, Karil Bialostosky’s Russian and Polish Jewish parents were publicly-promoting their Mexican born daughter as a co-leader of the Young Judeans.

Dettelbach failed to prosecute anyone in northern Ohio for violating the Logan Act, Espionage Act and Foreign Agents Registration Act during his time in office.  Law enforcement officers that included police officers, sheriffs, prosecutors and judges got off scot-free from having to worry about criminal charges for violating 18 U.S.C. 241 and 242 that Samaria Rice and other loved ones of citizens killed by police wanted.

The two federal laws were associated with the Violent Crime and Law Enforcement Control Act of 1994 and included sentencing upgrades from misdemeanors to felonies for cops, prosecutors and judges who engaged in conspiracies to violate rights under the color of law. The death penalty for conspiratorial cops, prosecutors and judges was also another upgrade to the controversial 1994 federal law.

Instead of enforcing more serious laws, particularly those related to espionage, treason and immigration, Dettelbach used former Cleveland building official Rufus Taylor to entrap American Negro contractors into a bribery scheme and pursued fake terrorists federal prosecutors and FBI agents created.  Dettelbach’s criminal prosecutions looked like those a police beat journalist would find in a local police blotter when one considers the build-up of IDF-friendly individuals like his wife calling themselves “Americans” and expressing allegiance to foreign soldiers on U.S. soil.

Right now in real time the FIDF is seeking money from inside the United States of America to support a foreign military invasion of Palestinian neighborhoods whose property owners have been targeted for evictions to make way for Jewish “settlers” with Brooklyn accents.

Children featured in the IDF movie Bialostosky-Dettelbach shared of them at ages six, seven and eight in 2015 are now a heavily-indoctrinated 12, 13 and 14 year olds.  If the pledges to the Israeli flag and IDF visits have been continual they’ve been influenced to support a foreign government and foreign troops secretly building an army of IDF potential forces on U.S. soil.  It’s a foreign armed forces whose history includes the slaughter of U.S sailors aboard the USS Liberty on June 8, 1967 and repeated threats to American lives.

Terrorists Menachim Biegun, Golda Mabovitch (Meir) and Ariel Scheinnerman (Sharon) controlled the “Israeli” government and IDF U.S. armed forces at the time called “Soviets” from Russia, Poland and the Ukraine.   They were involved in a “6 Day War” with Egypt and wanted U.S. weapons support for their sneak attack on Egyptian aircraft and bases.

In another sneak attack during the 6 Day War the IDF slaughtered 34 U.S. sailors aboard the USS Liberty and wounded another 174 by jamming the ship’s radio and radar and then attacking our sailors repeatedly in gunboats with the intent to kill them all.     Their desire was to deceive President Lyndon Johnson into believing Egypt’s armed forces had committed the heinous act in an attempt to secure arms support for their further militaristic activities in the Middle East.  The lives of “goyem” are of little consequence.

The IDF blamed Egypt for their attack during the 6 Day War for closing a “strait” to their ships.  The same IDF blamed the U.S. citizens aboard the USS Liberty for not flying an American flag that was still clearly visible after their murderous sneak attack.  They claimed the 75 minute attempted massacre was a mistake.

This support for foreign soldiers on U.S. soil is wrong on so many levels. America has a separate foreign policy agenda than the Russians, Polish and Ukrainians who control the government of Israel in Palestine. Raising over $500 million to support the Israeli Defense Forces creates the false illusion that the majority of citizens of the United States of America agree when we don’t. Increasingly American foreign policy is being hijacked by self-agenda’d immigrants and their descendants.

In 1954 the IDF planted bombs in Cairo, Egypt inside buildings Americans used during what was called then The Lavon Affair.  This was less than six years after illegal Russian, Polish and Ukrainian aliens and organized crime figures like Leonard Ratner, Meyer Lansky, Bugsy Siegel and Micky Cohen donated a total of $50 million to arm IDF terrorists against the Palestinian government in 1948.  President Dwight Eisenhower wasn’t giving the Soviets who’d taken over Palestine access to the weapons they wanted and the planted bombs were to, again, be blamed on Egypt. Ratner’s son, Albert Ratner, bragged in a video about how his father contributed $25,000.

The IDF as recently as May 15, 2021 bombed a building that housed an office of American citizens working for the Associated Press in the Middle East.   IDF forces claimed American journalists knew they were working in the same building as Hamas’ leadership.  Al Jeezera reporters rented space in the building as well.

According to the IDF the American journalists were given a warning to get out before the building was bombed.  The warning consists of IDF forces dropping an unexploded missile on the roof of a building before an explosion comes 10 minutes later.  Only God can help the handicapped.

Ohio FIDF organizers posed with IDF Staff Sergeant A whose face is hidden along with his concealed name. Retired Israeli Defense Forces Major General Meir Klifi Amir is the third man from the left.  Under John Edgar Hoover’s FBI, these men and women might be viewed as Soviet spies, arrested, criminally prosecuted and possibly deported.

Uniformed foreign soldiers from the IDF have no business on United States soil and their unsupervised presence here would under normal circumstances be seen as a violation of the Logan Act, Espionage Act as well as the Foreign Agents Registration Act.  Were Bialostosky not Dettelbach’s wife the Russian immigrant born in Mexico City might have been investigated for espionage or treason as a promoter of the IDF’s “movie” filmed on American soil in Beachwood, Ohio.  So would the leadership and members of the FIDF.  There is nothing “friendly” about the IDF when it comes to Americans as demonstrated by their history.

The Cleveland chapter of the FIDF takes some effort to hide the faces and conceal the names of the foreign soldiers they’re violating espionage and immigration laws to quarter on U.S. soil.  The concealment is alleged to be for the “safety” of the foreign soldiers recruiting and raising money used to discharge adjunct duties of the Israeli government in caring for its troops.  Other chapters on the FIDF website appear not to be so secretive of their interactions with the agents of a foreign government’s armed forces.

Locally, Harlan Diamond’s Landerhaven has been the host site of local FIDF annual “galas” for the IDF “heroes” who “protect us all.”  The “us” according to the FIDF’s website are Jews around the world.

The concept of a 160,000 man, woman and child armed ground forces of IDF “friends” operating openly but in secret inside the United States of America is more than implied by Klifi-Amir’s unreported, uninvestigated and unopposed presence here since 2014.

11th Congressional District candidate’s pledge aid to Israel but nothing for American Negroes because no one asked and none thought enough to offer

CLEVELAND, OH – Contenders to replace former United States Representative Marcia L. Fudge on the Democratic Party side of the campaign have participated thus far in two forums.  The first was on March 11, 2021 during a Zoom forum hosted by the Jewish Democratic Council of America.  The second was before a live audience at the African American History Museum on March 27.

Present at both forums were former State Senators Nina Turner and Jeffrey Johnson; former State Representatives John Barnes, Jr. and Bryan Flannery; Cuyahoga County council member Shontel Brown and Tariq Shabazz.  Republican contender Laverne Jones Gore told EJBNEWS she was not invited.  It’s interesting that an Irish Catholic Flannery can attend a majority American Negro event and speak but an American Negro can’t. Former State Senator Shirley Smith declined to attend the live event at the African American History Museum organized by Michael Fields.

“Democrats have lost their way,” Laverne told EJBNEWS.

Ward 7 councilman Basheer Jones, who just moved into the city from Cleveland Heights in December 2020, was invited but backed out.  He had called police on over 200 American Negro men, women and children during a previous event.  He opted for an event with Chinese aliens in China Town.

At the Jewish forum organized by Russian, Polish, Ukrainian and Syrian Jews the 11th Congressional contenders promised everything the foreign government of Israel wanted.  The $3.8 billion in aid annually.  No support for the boycotts of Israel.  A two-state solution.

At the African American History Museum no one asked, specifically, if the $38 billion in aid to Israel over 10 years would be better spent improving home ownership and business opportunities for American Negroes.  Israel offers its citizens free health care off U.S. money.   Only one of the contenders has a military background, Tariq Shabazz.

None seem affected by questions asking them to continue arming a nation the Central Intelligence Agency and Federal Bureau of Investigation identify as this nation’s number #1 spy threat.  None asked the callers supporting Israel how they felt about the Israeli Defense Forces on June 8, 1967 “intentionally” slaughtering 34 sailors aboard the USS Liberty and wounding another 171.  It suggests that candidates seeking the Congressional seat have not read the nation’s espionage laws to know Americans are prohibited under the Logan Act of 1799 from writing to foreign officials; and under the Espionage Act of 1917 from exchanging information with them.

How would an American who has obeyed espionage laws know Israel’s government wants $3.8 billion annually?  Advocates for a foreign government must register as foreign agents pursuant to the Foreign Agents Registration Act.  An unregistered foreign government advocate is a foreign agent.  None asked host Ron Klein if he was an agent of the Israeli government.

During both forums the Democratic contenders did not say, specifically, what they were going to do to benefit the nation’s largest ethnic demographic group.  American Negroes.  No one asked.

Laverne Jones Gore is an American Negro and a Republican contender for the 11th Congressional seat once held by U.S. Rep. Marcia Fudge.  She wasn’t invited to speak at the candidates forum Democrats hosted at the African American History Museum.  Has anyone compared Democratic ballots to Republican ballots?  There were more American Negro candidates on the Republican ballot for the court of common pleas than Democrats.

EJBNEWS has obtained and is featuring the two forums above.  We intend to keep our readers updated about the statements the candidates are making to different constituent groups so 11th District voters can compare and judge for themselves.

Readers attending forums or candidate fundraisers are welcomed to send EJBNEWS video recordings of the events; and the words of the candidates.  The email address is eric@ejbnews.com

[NOTE: The first video was supplied by journalist and podcaster Larry Gardner.  Gardner said he arrived about 15 minutes into the forum].

HBCU’s targeted by unregistered Communist Chinese government agent Julia Wilson with help from Morgan State University’s president

CLEVELAND, OH – College and university presidents along with local school district superintendents and boards have been targeted for infiltration by the Communist Peoples Republic of China.  100 colleges and universities, and 42 Historically Black Colleges and Universities (HBCU), appear to be targets of this covert espionage through diplomacy.

Ohio United States Senator and Republican Rob Portman, in his capacity at the time as the Chairman of the Permanent Subcommittee on Investigations (PSI), released a 196-page bipartisan report in February 2019 detailing how the Communist Chinese government was combining “covert operations with diplomacy” at more than 1000 American colleges, universities and school districts.  The committee was co-chaired by ranking member and Democrat Tom Carper.  The coincidental timing of their report came one month after Wilson Global’s first full FARA filing.

For the past six years, Portman said the Communist Chinese government, or the Peoples Republic of China, directed $158 million to U.S. school districts operating “Confucius Institutes.”  The Confucius Institutes are the brainchild of the Chinese government’s Hanban and funded by the Chinese Ministry of Education.

The U.S. Senate commitee Portman led identified how public and private education officials are entering Memorandums of Understandings (MOU) with Communist China to teach its language and culture to students in K-12 and in our nation’s colleges and universities without any United States Department of State or Justice Department oversight.   Some of the agreements contain “non-disclosure” language no university, public or private official has the authority to sign.  The very nature of local citizens interacting with the officials of foreign governments and their agents violates federal espionage laws.

A Foreign Agents Registration Act (FARA) filing from a public relations firm named Wilson Global show its owner, Julia A. Wilson, has created cultural exchange relationships between China and 42 Historically Black Colleges & Universities (HBCU).  They are among the 100 colleges and universities identified in the U. S. Senate committee’s investigation.

Federal espionage laws dating back to the Logan Act of 1799 instructs everyone residing with the United States of America that they have no authority whatsoever to initiate “correspondence” with the officials of a foreign government.  The Espionage Act of 1917 makes the language even stronger.  The 1938 Foreign Agents Registration Act (FARA) requires anyone operating on behalf of a foreign government or promoting its interests, whether contracted to do so or voluntarily, to register with the United States Department of Justice prior to the engagement.  Foreign communications are directed and supervised by the United States Department of State.

President Joe Biden’s rush to make China look good before Republicans get “their turn” to roll out impeachment proceedings on Hunter Biden’s role with the Communist government as a paid and unregistered agent is being rejected by Ohio United States Senator Rob Portman.

All of the “registered” foreign agent or “propagandist’s” meetings on behalf of the foreign government must be documented and filed with the United States Department of Justice.  The identification of the meetings foreign agents examine and keep on file include date, time, name and title of the person with whom they’re either meeting, calling or emailing.  Every communication is required to be shared with the USDOJ.

These are but some of the laws former Special Counsel Robert Mueller used in his indictments of Trump campaign associates Paul Manafort, Michael Flynn, Rick Gates and 31 others.  No university or school district board, superintendent, president or otherwise, public or private, has extra authority to engage in foreign communications without federal government oversight.

Before he left office, President Donald Trump was focusing the heads of the United States Department of State, United States Department of Justice and United States Department of Education on ensuring the nation’s college and university campuses were obeying federal immigration and espionage laws.  More than 1.1 million foreign students were being allowed to steal educational opportunities from Americans … annually.  Access to our universities and colleges provides foreign nationals with criminal intent direct access to our “national defense and trade secrets.”

The only American during his term in office, who was authorized by law to determine United States foreign policy towards the Communist Peoples Republic of China was President Donald Trump whether any individual citizen agreed with his views or not. Everybody else cutting deals with Communist China, without authorization from the United States Department of State, and registering as its propagandists with the United States Department of Justice’s Foreign Agents Registration Act division, whether a paid or volunteer China backer, has Paul Manafort, Rick Gates and Michael Flynn problems.

53 percent of Case Western Reserve University’s (CWRU) class of 2024 consisted of alien students before the pandemic.  It is inconceivable to think of CWRU qualifying for federal and state funding when it’s faculty is educating more aliens than Americans.

Julia A. Wilson founded Wilson Global in South Africa in 1994 and did not register as the agents of any foreign government during the administrations of President George W. Bush or President Barack Obama.   It was during the Trump administration on August 31, 2018 that she “finally” registered with the United States of Department of Justice as an agent of the Chinese government as she was required to do by law before she entered her first contract years earlier.

Julia A. Wilson describes her work for the Communist Chinese government in the following manner.

China-United States Exchange Foundation (CUSEF) was established with the purpose of further improving communications and enhancing understanding between the peoples of China and the United States. CUSEF accomplishes their mission by fostering open dialogue between the public policy arena, think tanks, academia, media and the business communities of both countries, particularly dialogue based on Foundation-supported policy-oriented research on various areas of common interest between China and the United States. CUSEF was founded by its Chairman, Mr. Tung Chee Hwa, the current Vice Chairman of the National Committee of the Chinese People’s Political Consultative Conference, People’s Republic of China, and the first Chief Executive of the Hong Kong Special Administrative Region (“HKSAR”), People’s Republic of China. As international consultants to CUSEF, Wilson Global Communications is the first African American-owned company CUSEF has contracted in the world. Wilson Global is tasked with assisting CUSEF to build and improve dialogue between China and African American business, education, and civic leaders.

Wilson Global’s FARA filings show Julia A. Wilson individually reaching out to federal officials and others to discuss President Donald Trump’s administration’s crackdown on behalf of her Communist Chinese government client.  His demanding that universities and colleges obey federal espionage and reporting laws weren’t good for her bank balances.

Dr. David Kwabena Wilson was working with Julia A. Wilson’s public relations firm in 2014, and leading a delegation to China to sign a Memorandum of Understanding four years before she registered as an agent of the Communist Chinese government. When David Kwabena Wilson was inviting HBCU presidents to join him on the trip to the Communist nation, and signing agreements on behalf of them all, he should have registered like Julia A. Wilson with United States Department of Justice as a foreign agent as he was operating far outside the legal authority of a “state” university president spending federal, state and local tax dollars under federal and state laws and regulations. I’m confident some official administered this man an “oath of office” where he swore to uphold the U.S. Constitution giving Congress the exclusive authority to determine matters of foreign affairs; and to obey federal and state laws.

Julia A. Wilson’s nationality is not identified on what appears to be a FARA filing with incomplete information.  What her own filings show is she’s Chinese Communist party Boss and President Xi Jinping’s “Black” face front to the nation’s HBCU’s.

Until August 31, 2018, Wilson did not previously-disclose in federal documents her paid agent’s work inside the United States of America as a propagandist for the Communist People’s Republic of China.  By then the officials of 42 HBCU’s had been ensnared in a series of unlawful activities with Communist Chinese agents that violated the nation’s espionage laws.

Communism is outlawed in the United States of America pursuant to the National Security Act of 1950. The presidents and board members of the 42 Historically Black College and Universities (HBCU) she hooked up with Communist Chinese officials now have their own federal law compliance problems.

It’s particularly so if they have joined the “HBCU – China Scholarship Network” Julia A. Wilson promoted years before she registered as Communist China’s domestic propagandist with the United States Department of Justice.  Wilson did answer yes on her FARA filings to working for the Chinese government years before filing.

Dr. David Kwabena Wilson did not use Morgan State University letterhead to forward a letter to HBCU presidents on August 21, 2018, about 10 days before Julia A. Wilson registered for the first time on August 31, 2018 as a paid propagandist of the Communist Peoples Republic of China. He did use his Morgan State University title under the Wilson Global letterhead which identifies the entity Julia A. Wilson promotes that is funded by the Peoples Republic of China. Before he forwarded this letter on behalf of the HBCU – China Scholarship Network, Dr. David Kwabena Wilson should have registered with the United States Department of Justice’s Foreign Agents Registration Act division. This letter makes it appear as if Dr. D.K. Wilson is working for Wilson Global and her HBCU-China Scholarship Network with the Communist Chinese government. He appears to be using his public office to enrich himself and Julia.

Since August 31, 2018, Wilson has reported the help she’s been receiving from Morgan State University President David Kwabena Wilson to the United States Department of Justice in her FARA filings.  The Morgan State University president presents more than the appearance that he’s using his public office to help Julia

Wilson as he individually invited other HBCU presidents to join him and the Chinese government’s propagandist and agent bearing his last name on trips to China.  I doubt if any of the nation’s HBCU presidents know their names are in Julia A. Wilson’s Wilson Global FARA filings identifying them as potential espionage and propagandist law-violating targets.

Morgan State’s David Kwabena Wilson has been audacious enough to sign a Memorandum of Agreement (MOU) with a Communist Chinese national named Zhang Baojun representing the Peoples Republic of China.  The size of the egos of university presidents and corporate chairmen operate far outside the boundaries of espionage laws they have no authority to violate whether they know them or not.

When elected officials meet their “new friends” they should investigate them. Julia A. Wilson was meeting with numerous elected officials, journalists, appointed officials and others long before she registered as an agent of the Peoples Republic of China. If her name appears on campaign finance reports the donor money is coming from China.

Morgan State University’s former and long-term board chairman, Dallas Evans, warned other board members in 2010 that Wilson’s management was riddled with compliance issues.  He accused the university’s president of being a self-promoter instead of a competent and compliant manager.

A January 2019 audit conducted by Maryland’s Department of Legislative Services Office of Legislative Audits confirms the former board president’s opinion of his management. Dr. Wilson and his management team and board were found to be in violation of 10 major areas of federal and state laws.  Evans was removed as board chairman in 2013 when it appears the Wilson’s started operating as unregistered agents of Communist China.

Her FARA filings with the United States Department of Justice show Julia A. Wilson being copied on correspondence coming from Morgan State University President David Kwabena Wilson promoting the university’s China partnership and a 2013 MOU he signed with an agent of the People’s Republic of China.

Julia A. Wilson’s now completely transparent website describes the public relations and marketing firm she operates as offering “customized services on building and bridging relationships between American and foreign leaders and organizations in education, business, media, and civic affairs.” 

 

Morgan State University president David Kwabena Wilson, Phd, was accused by former board chairman Dallas Evans of violating numerous federal and state laws during his administration of the federal and state government funded education institution.  In this photo he’s signing a Memorandum of Agreement with Communist Zhang Baojun of the Peoples Republic of China.

As soon as he took office, President Joe Biden issued an executive order that benefited his crackhead son Hunter Biden.  According to Biden, China is good and criticism of Asians is now xenophobia

The President’s son collected $6 million from one Chinese firm and was offered $10 million a year for the hook-up to his Vice President father during the presidential administration of Barack Obama.  A politician who’s palms are being “greased” will say and do anything.  I have every expectation that the Biden’s and Vice President Kamala Harris will face investigations and impeachments in Congress.

Portman sent Biden a letter on February 10, 2021 warning him to re-think.  Biden’s had prostate cancer problems.  Lupron, the drug used to lower a man’s testerone levels in preparation for prostate cancer surgery, causes dementia in 90 percent of men over the age of 66.  Read Portman’s warning.

“The Biden Administration’s decision to withdraw this rule is deeply disappointing and surprising considering the serious nature of China’s efforts to expand its influence operations inside the United States.  I urge them to reconsider. As the bipartisan report which I co-authored in 2019 documents, there is a stunning lack of transparency about how Confucius Institutes operate inside the United States. 

We learned that schools in the United States—from kindergarten to college—have provided a level of access to the Chinese government that can stifle academic freedom and provide Confucius Institute students with an incomplete, and sometimes inaccurate, picture of Chinese history, government actions, and policies that run counter to U.S. interests at home and abroad.

Our PSI report documented how China and the Chinese Communist Party provides no reciprocity and has systematically shut down key U.S. State Department public diplomacy efforts on Chinese college campuses.  Absent full transparency regarding how and where Confucius Institutes operate, Confucius Institutes should not operate in the United States and be allowed to influence American students.”

The title page to United States Senators Rob Portman and Tom Carper’s bi-partisan report.

Nowhere in Title 33 of Ohio’s Revised Code are Ohio’s school districts, universities and libraries authorized to engage in acts that have created the following national security issues a new governor and state school board will have to aggressively enforce.  Below is a sample of Portman’s findings.

  • While China expanded Confucius Institutes in the U.S., it failed to provide appropriate reciprocity for U.S. officials and educators in China. The State Department documented at least 80 examples of Chinese inference with American public diplomacy efforts from January 2016 to July 2018. The State Department shut down an entire public diplomacy program to create partnerships between U.S. and Chinese schools in China because of Chinese government interference.
  • The Chinese government controls nearly every aspect of Confucius Institutes at U.S. schools, including its funding, staff, and all programming. It even has veto authority over events and speakers.
  • The Chinese government also funds teachers for Confucius Classrooms in the United States, which teach Chinese language and culture in kindergarten through 12th grade schools. There are over 1,000 Confucius Classrooms worldwide and more than 500 in the United States. Expanding the Confucius Classroom program is a priority for the Chinese government.
  • There is little transparency in the selection of Chinese directors and teachers that staff Confucius Institutes. They are vetted and hired by the Chinese government, and U.S. universities choose from a pool of applicants approved by the Chinese government.
  • Chinese directors and teachers at Confucius Institutes pledge to protect Chinese national interests. Chinese teachers should “conscientiously safeguard national interests” and their contract terminates if they “violate Chinese law” or “engage in activities detrimental to national interests.”
  • Some U.S. schools’ contracts with the Chinese government include non-disclosure provisions and require adherence to both U.S. and Chinese law.
  • The State Department does not collect visa information related to Confucius Institutes. As a result, the State Department does not know how many Confucius Institute teachers are here or which U.S. schools host them.
  • U.S. schools failed to comply with statutory requirements to report foreign gifts to the Department of Education. Nearly 70 percent of U.S. schools with a Confucius Institute that received more than $250,000 in one year for Confucius Institutes failed to properly report that information to the Department of Education.
Some insight about the content in the 196-page report all education officials at every level should read.

With only 29 of the schools given a grant and instructions from the United States Department of State to operate in this nation, Portman’s committee noted that the majority of the Confucius Institutes operating at over 1000 universities, colleges and school districts across the United States of America and in East Cleveland were not authorized.  The majority of Ohio universities are operating Confucius Institutes.  So does the Cleveland Municipal School District under its Russian superintendent, Eric Gordon.

Portman’s report revealed that the Chinese government decided not to move forward with districts approved by the U.S. Department of State approved contracts.  Too many restrictions and no “non-disclosure agreements.”  Communist Chinese officials chose, instead, to operate through individual American citizens who were willing to disregard the nation’s laws.

I have every confidence that neither ex-superintendent Myrna Loy Corley, board president Una Keenon and the board’s members have any knowledge of federal espionage laws, immigration laws; or knew the full picture of the Confucius Institute program former East Cleveland school board member Patricia Blochowiak was pushing.  I doubt they know that for every alien or immigrant hired, they’re required to have them “first” complete an I-9 that’s filed with the United States Department of Labor.

The Communist-controlled Confucius Institutes are operating under the guise of existing to foster “cultural exchange;” but appear to have become entities created to infiltrate more than 100,000 illegal Communist Chinese aliens and workers into the nation that China refuses to take back.   American students are learning the language of a people the United States Congress enacted the Chinese Exclustion Act in 1891 to keep out between 1891 and 1945.

Non-English speaking Russians, Polish and Ukrainians were also included in the “keep them out” federal law restrictions.  This nation wanted nothing to do with Communists and Communism.  Today criticism of these groups of illegal aliens will cause one to be labeled an anti-semite or a xenophobe.

The Confucius Institute affiliation in 96 percent American Negro populated East Cleveland appears to have come from former school board member Patricia Ann Blochowiak, a Polish American with a medical degree and long-time inactive medical licenses in two states.  Poland at one period in its history belonged to the Soviet Union and is the location of a town called Treblinka where German Adolph Hitler’s Nazi’s operated extermination camps.

Blochowiak has been evasive in our individual “email” discussions about her family’s ancestral history and activities during Eastern Europe’s ethnic cleansing blood lusts.  Sources say she’s taken repeated trips to China. Russia’s next door neighbor.

I would not encourage East Cleveland officials to send American Negro children to be abused in China.  The Communist nation’s leaders just showed their true colors during the CoVid pandemic.  African “residents” of the nation were ordered not to enter restaurants or other public facilities; and kicked to the streets out of their homes.

Blochowiak was once licensed to practice medicine in Minnesota and Ohio.  Each state’s medical board identifies her licenses as being inactive since November 30, 1993 in Minnesota and July 1, 2001 in Ohio.  Blochowiak graduated from the University of Wisconsin Medical School on May 28, 1978.

Former licensed physician and Eastern European of Polish descent Patricia Blochowiak calls Americans who want immigration laws enforced “xenophobes.” Her labeling self-justifies her use of an East Cleveland school board seat to promote her “personal” foreign policy interests and relationship with Communist China. Any American who interacts with Communist Chinese officials, and who seeks to impose what they’ve learned in China here, whether paid or as a volunteer, must register with the USDOJ as a foreign agent.

For less than one year in 1988, Blochowiak’s Linked In page reads that she functioned as a health care worker at the Sen Lin Hu camp owned by Concordia Language Villages in Bemidji and Cass Lake, Minnesota.  The group has created balkanized language and culture villages representing Russia, Korea,  France, Spain and Norway.  They also have a Chinese village where its members live in “jias.”  It’s another name for communal families.

Blochowiak speaks some German, Spanish and Mandarin Chinese, according to her Linked In page.  Her only time as a licensed physician appears to be the five years she worked at MetroHealth between 1992 and 1997.   It also appears to be the only other time she held a job.  Unlicensed physicians can perform non-medical services.  According to her social media page, Blochowiak has been a volunteer and a promoter of left-wing extremists like Russian U.S. Senator Bernard (Gitman) Sanders.

Her profile further identifies Blochowiak as a member of Citizens for Global Solutions.  The organization wants a global government that consists of “democratic federation of nations” to resolve global disputes and not the United Nations.  Its website links to the Anti-Defamation League when referencing “racism.”  The majority of its board’s members have names foreign to the United States of America.  Several appear to be Russian.

One row of the type of “one world order” books the Citiziens for Global Solutions promotes. Patricia Blochowiak is a member.

China began looming large in the lives of East Cleveland residents right before and after Blochowiak was elected to the East Cleveland board of education in the November 2007 election.  Her term began on January 1,2008.  She served during my time as the city’s mayor between January 1, 2006 and December 31, 2009.

There is an Educate Cleveland blog that on January 27, 2008 promoted Donshon Wilson’s attempt to raise money to take 51 members of the Shaw High School Band to China for $3500 each.  Parker Hannifin, with an office in Moscow, kicked in $50,000.

Members of East Cleveland council wanted to allocate $10,000 in municipal funds for the travel.  I said no.  My director of law, the late Almeta Johnson, warned council that municipal funds fell under Title 7 and education funds fell under Title 33 of Ohio’s Revised Code.  One couldn’t be used for the other.

Almeta met with Superintendent Myrna Loy Corley, who had been appointed by the board when I served on the Financial Planning & Supervision Commission after the district was placed in fiscal emergency.  Under Ohio law municipal law directors advise and deliver legal opinions to municipal school districts.

I don’t recall the details of how it materialized; but I recall Myrna coming up with a balance of the $500,000 needed.  I know Blochowiak was behind the Chinese culture and language classes in the school district.  I do not, yet, know how extensively the Communist government-backed program was injected into the thinking of East Cleveland children.  I do not recall a Chinese cultural exchange program taking place during my four years as the city’s mayor.

I remember when Una Keenon and the East Cleveland school board “censured” Blochowiak from speaking and leading any committees.  Voters finished the job when she lost in 2019.  It’s been shared with me that Blochowiak is planning, again, to campaign for a seat on the East Cleveland board of education in 2021.  Her politics for that city are still wrong … again.

I served in the United States Air Force in Udorn Thailand at the 432nd USAF hospital; and as a security police augmentee during the fall of Saigon between 1974 and 1975 at the Central Intelligence Agency’s lead “Air America” operation.  I was there in April 1975, 120 miles from Saigon, for Operation Eagle Pull and Operation Frequent Wind when South Vietnam fell to Communist China-backed North Vietnam.  Mel Gibson and Robert Downey’s “Air America” film was bullshit.  An individual holding a public job and not discharging its duties is not a “government agent.”  They’re a criminal.

When President Donald Trump stopped foreign students from entering the nation during the CoVid pandemic it cost Julia Wilson lots of money. She reached out to members of Congress as a registered agent of the Communist Chinese government to express her foreign client’s thinking.

After Communist North Vietnam overran South Vietnam with the help of Communist China, I remember the discussions on our Thai ally’s side of the border about the “re-education camps.”  Former South Vietnamese soldiers, government workers, politicians, etc. were required to register with their Communist North Vietnamese captors.

Thousands were detained and left starving to death in the re-education camps after they were forced into writing confessions.  Everywhere there is Communism there are mass graves.

Biden’s pro-China executive orders have everything to do with his family living well off Chinese money from his unregistered foreign agent son … Hunter.  Xi Jinping pays his agents well.

Trusting American Negroes have always been particularly vulnerable targets for Communist infiltration.  Everybody pushing a “we love Black people” agenda in our neighborhoods and communities isn’t always a friend.

The Russian Johnson & Johnson CEO Ohio sued in 2019 for sending 50 million fentanyl doses to Cuyahoga county and more to the state reported $24.5 billion in 4th quarter earnings

/

CLEVELAND, OH – Russian “American” Alex Gorsky is the man in the feature image who leads Johnson & Johnson pharmaceuticals and supplies as its chief executive officer.  He earns over $20 million a year.  On January 26, 2021 he delivered a report to the board on Johnson & Johnson’s 4th quarter earnings.  Revenue after expenses was $22.48 billion.  Big Pharma.  There’s profit in price-gouging the poor for medicine.  I’ve shared a complete transcript of his call below.

In 2019 Gorsky led Johnson & Johnson to settle $20 million in claims with Cuyahoga and Summit counties for all the fentanyl he shipped here.  50 million doses for Cuyahoga County … alone.  There are 1.2 million residents in our county and not all of us use narcotics. What did the two county council’s do with the $10 million each?

Right before the federal trial Gorsky’s company was involved in with others here in Cleveland, CoVid 19 was thrust into the global spotlight.  All of a sudden fentanyl dealers like Gorksy became CoVid vaccine “heroes” as he announced Johnson & Johnson would lead the way to a cure.  Just like it did with fentanyl.  No.  I’m not taking a vaccine “he” leads Johnson & Johnson to create.  The man’s a drug dealer.  5000 deaths a year in Ohio.  I’m good.

If you’re looking for anything profound in the “earnings” call Gorsky held with Johnson & Johnson’s money managers forget it.  All he does is basically report on the sales of the pharmaceuticals people are using … globally.

For your own expansion, investigate the names and backgrounds of every person identified in the call.  Not all are “American.”  Gorsky has no authority to communicate with the officials of foreign governments just because he’s a corporate CEO with a “global” business.  His desire to do “global” business doesn’t give him special privileges to ignore the Espionage Act and Logan Act.

Johnson & Johnson (JNJ) CEO Alex Gorsky on Q4 2020 Results – Earnings Call Transcript

Jan. 26, 2021 2:02 PM ETJohnson & Johnson (JNJ)1 Comment

Q4: 2021-01-26 Earnings Summary

EPS of $1.86 beats by $0.03 | Revenue of $22.48B (8.33% Y/Y) beats by $854.38M

Johnson & Johnson (NYSE:JNJ) Q4 2020 Results Conference Call January 26, 2021 8:30 AM ET

Company Participants

Chris DelOrefice – VP, IR

Alex Gorsky – Chairman and CEO

Joe Wolk – EVP and CFO

Conference Call Participants

Terence Flynn – Goldman Sachs

Larry Biegelsen – Wells Fargo

David Lewis – Morgan Stanley

Louise Chen – Cantor Fitzgerald

Chris Schott – JP Morgan

Joanne Wuensch – Citi

Matt Miksic – Credit Suisse

Danielle Antalffy – SVB Leerink

Bob Hopkins – Bank of America

Operator

Good morning. Welcome to Johnson & Johnson’s Fourth Quarter 2020 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. The call is being recorded. [Operator Instructions] I would now like to turn the call over to Johnson & Johnson. You may begin.

Chris DelOrefice

Good morning. This is Chris DelOrefice, Vice President of Investor Relations for Johnson & Johnson. Welcome to our Company’s review of business results for the fourth quarter and full year of 2020 and our financial outlook for 2021.

Joining me on today’s call are Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Joe Wolk, Executive Vice President and Chief Financial Officer.

A few logistics before we get into the details. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com, where you can also find additional materials including today’s presentation and associated schedules.

Please note that today’s presentation includes forward-looking statements. We encourage you to review the cautionary statement included in today’s presentation which identifies certain risks and factors that may cause the Company’s actual results to differ materially from those projected. In particular, there’s significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic. This means that results could change at any time and the contemplated impact of COVID-19 on the Company’s business results and outlook is a best estimate, based on the information available as of today’s date.

A further description of these risks, uncertainties and other factors can be found in our SEC filings including our 2019 Form 10-K and subsequent Form 10-Qs, along with reconciliations of the non-GAAP financial measures utilized for today’s discussion to the most comparable GAAP measures are also available at investor.jnj.com. Several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.

Moving to today’s agenda. Alex will provide perspective on our overall results and business highlights for the year. I will review the fourth quarter sales and P&L results for the corporation and the three business segments. Joe will conclude by providing insights about our cash position, capital allocation deployment, and our guidance for 2021. The remaining time will be available for your questions. We anticipate the webcast will last up to 90 minutes.

I would now turn the call over to Alex to share our overall results and business highlights.

Alex Gorsky

Thank you, Chris. And thank you everyone for taking time to join us today to discuss our full year 2020 results and outlook for 2021. At the start of last year, no one could have imagined just how drastically our lives were about to change because of a virus that would impact billions of people around the world. By any measure, 2020 was a year dominated by uncertainty, yet the pandemic also helped to clarify both our priorities and our values. And within Johnson & Johnson, it has illustrated the power and importance of our credo in guiding our actions to meet the needs of all our stakeholders.

Now because of COVID-19, we now have a deeper appreciation on just how pivotal good health is to our safety, security, and prosperity and as a society. We have a profound respect and gratitude for all the doctors, nurses and hospital staff serving on the frontlines of care, the everyday heroism of the essential workers who show up every day to keep the world’s critical infrastructure up and running, and expectations that companies can and should help drive positive change in society are higher than ever.

As the world’s largest and most broadly based global health care company, Johnson & Johnson was built for times like these. We’ve been leading through the world’s biggest public health challenges for over a century. And today, our diversified businesses touch so many parts of people’s lives. We had both, the ability and the responsibility to act when the COVID-19 outbreak turned into a global pandemic.

Within weeks of the DNA sequencing of the COVID-19 virus, Janssen scientists were working 24×7 to identify the most promising lead candidate for a vaccine. I’m proud of the progress of our COVID-19 vaccine candidate, and the fact that we moved so quickly while maintaining the highest level of science and safety standards. This is truly a remarkable accomplishment, and a testament to the ingenuity and determination of our vaccine and supply chain teams. We look forward to sharing further details from our Phase 3 study by early next week.

Additionally, I’m just as proud of the ways each of my Johnson & Johnson colleagues have gone above and beyond the call of duty to provide uninterrupted access to our medicines, embrace radically new ways of working, and use the full breadth and depth of our expertise to deliver our important medicines and products to patients and consumers and support health care systems that have been overwhelmed by the pandemic.

The fact that we’ve been able not just to weather this crisis but bring our broad-based capabilities to support this crisis and deliver on a shorter term top and bottom line business goals, while increasing our investments in innovation to record levels is a remarkable testament to our purpose-driven culture, the core strengths that characterize our Company for over a century, execution, innovation, and people.

Our relentless focus on excellence and execution is key to meeting the needs of all our stakeholders today and tomorrow. The performance of our business in 2020 reflects the continued confidence from patients, physicians, customers and consumers in our life-saving medicines and products.

Our Pharmaceutical business performed well above market, kept pipeline submissions and approvals on track, and exceeded patient enrollment in clinical trials compared to 2019. Our Consumer Health business also performed above market for the year and our Medical Devices business demonstrated resiliency and agility leading to a strong second half recovery.

Our unparalleled scientific expertise, allowed us to create life-enhancing innovation. Our R&D colleagues across Johnson & Johnson have continued to advance our robust pipeline of innovative and transformational new products. Of note, we initiated our U.S. filing for our BCMA Car-T in multiple myeloma in December. In addition, we filed amivantamab for the treatment of Exon 20 mutations in non-small cell lung cancer in the U.S. and Europe.

Our Medical Devices business made a strong progress advancing our pipeline, despite the pandemic, achieving and even accelerating certain key milestones throughout the year. As you heard from Ashley, Dr. Moll and the team at the Medical Devices Update in November, we are developing an end-to-end the digital ecosystem across three robotics platforms, and we achieved a significant milestone this month, receiving FDA clearance for our VELYS Robotic-Assisted Solution.

We believe the industry is just starting to unlock the full potential of benefits of robotic and digital technologies. Johnson & Johnson is well-positioned to bring innovative, differentiated solutions to the surgery suite over the next 10, 20 and 30 years.

I’m also very proud of the great work from our supply chain colleagues in driving improvements and efficiencies over the past year. Gartner even honored Johnson & Johnson with a number 3 ranking across all industries on its Annual 2020 Supply Chain Top 25 Index. That’s up five spots from our 2019 ranking. Gartner also awarded Johnson & Johnson the number one spot on its 2020 Health care Supply Chain Top 25, citing our commitment to continuous improvement while putting innovation into practice, particularly in a response to the COVID-19 pandemic. And finally, we are powered by our people, purpose and value system. More than 75 years since it was authored, our credo continues to guide all 135,000 of us at Johnson & Johnson.

So, with that in mind, I want to highlight a recent appointment to our Board of Directors, an incredibly high honor awarded to one of our own directors. In December, Johnson & Johnson appointed retired U.S. Army Lieutenant General and former U.S. Army Surgeon General, Dr. Nadja West to our Board of Directors. Dr. West’s accomplished health care background in addition to her deep strategic leadership experience are strong additions to our Board of Directors.

In October, Johnson & Johnson Board Director, Dr. Jennifer Doudna, along with her colleague, Dr. Emmanuelle Charpentier was awarded the 2020 Nobel Prize in Chemistry for the revolutionary discovery of CRISPR/Cas9 gene editing considered to be one of the most significant breakthroughs in molecular biology in the past decade. We are truly proud of a recognition for this incredible work.

Our commitment to diversity, equity and inclusion in both, our workforce and the communities at which we serve has always been an important part of our culture. However, the past year has also shown a spotlight on the fact that we can all do more. To that end, I am proud of our Race to Health Equity platform launched in November. Our Race to Health Equity aims to help improve racial equity by eliminating health inequities for people of color and our $100 million commitment to invest in and promote health equity. I’m excited to be part of this progress and for Johnson & Johnson to play a part in impactful, lasting change. And most importantly, the talented and committed people at Johnson & Johnson drive our success by putting the patients and consumers we serve around the world at the forefront of all we do. We think and rely on them to continue to innovate, execute and focus on our shared purpose to deliver better health for everyone everywhere.

I look forward to addressing your questions during the Q&A portion of the webcast. Right now, I’ll turn the call over to Chris to share details related to our performance for the quarter. Thank you. Chris?

Chris DelOrefice

Thanks, Alex.

Now, to recap the fourth quarter. Worldwide sales were $22.5 billion for the fourth quarter of 2020, an increase of 8.3% versus the fourth quarter of 2019. Operational sales growth, which excludes the effect of translational currency, increased 7.1% as currency had a positive impact of 1.2 points. In the U.S., sales increased 9.6%. In regions outside the U.S., our reported growth was 7%. Operational sales growth outside the U.S. was 4.3% with currency positively impacting our reported OUS results by 2.7 points. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 7.3% worldwide, 9.6% in the U.S. and 4.8% outside the U.S.

As referenced on prior calls, I would like to remind everyone that our 2020 fiscal year included an additional week. Since this week occurred during a holiday period, it does not represent a full week of sales but rather a few more shipping days with these additional shipping days adding approximately 4 points to the quarterly sales growth rate and 1 point to the annual growth rate. This can be roughly applied across all segments. The additional sales were more heavily skewed to the U.S. For the enterprise, offsetting this sales benefit was the estimated negative impact of the COVID-19 pandemic. Lastly, while these few shipping days added to sales, we also had a full week’s worth of operating costs. Therefore, the impact to earnings was negligible.

Turning now to earnings. For the quarter, net earnings were $1.7 billion, and diluted earnings per share was $0.65 versus diluted earnings per share of $1.50 a year ago. Excluding after-tax intangible asset amortization expense and special items for both periods, adjusted net earnings for the quarter were $5 billion and adjusted diluted earnings per share was $1.86, representing decreases of 1.2% and 1.1%, respectively, compared to the fourth quarter of 2019. On an operational basis, adjusted diluted earnings per share declined 3.2%.

For the full year 2020, consolidated sales were $82.6 billion, an increase of 0.6% compared to the full year of 2019. Operationally, full year sales grew 1.2% with currency having a negative impact of 0.6 points. Sales growth in the U.S. was 2.5%. In regions outside the U.S., our reported year-over-year change was negative 1.3%. Operational sales growth outside the U.S. declined by 0.2% with currency negatively impacting our reported OUS results by 1.1 points. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 1.5% worldwide, 2.8% in the U.S. and 0.2% outside the U.S.

Net earnings for the full year 2020 were $14.7 billion, and diluted earnings per share was $5.51 versus diluted earnings per share of $5.63 a year ago. 2020 adjusted net earnings were $21.4 billion, and adjusted diluted earnings per share was $8.03, representing decreases of 8.1% and 7.5%, respectively, versus full year 2019. On an operational basis, adjusted diluted earnings per share decreased by 7.8%.

Beginning with Consumer Health, I will now comment on business segment sales performance for the fourth quarter, highlighting items that build upon the slides you have in front of you. Unless otherwise stated, percentages quoted represent the operational sales change in comparison to the fourth quarter of 2019 and therefore exclude the impact of currency translation. While not part of the prepared remarks for today’s call, we have provided additional commentary on our website for the full year 2020 sales by segment to assist you in updating your models.

Worldwide Consumer Health sales totaled $3.6 billion and grew 2% with growth in the U.S. of 2.7% and 1.5% outside of the U.S. Consumer Health delivered strong above-market growth due to our Oral Care, Wound Care and OUS Skin Health/Beauty businesses partially offset by the negative impact of COVID-19, primarily in our OTC business and the SKU rationalization program, which predominantly impacted Baby and Skin Health/Beauty outside the U.S. E-commerce growth continues to be strong across regions and franchises.

Over-the-counter medicines had a decline of 1.5%. In the U.S., OTC sales were flat and the OUS declined by 2.9%. Globally, results were negatively impacted by COVID-19 restrictions, resulting in lower cough, cold and flu incidences, impacting children’s TYLENOL, global cough and cold and digestive products. Offsetting these declines was strong adult TYLENOL market and share growth attributed to elevated demand, driven by COVID-19, ZYRTEC share growth, partially due to competitive out-of-stock and strong market growth in anti-smoking aids in EMEA.

The Skin Health/Beauty franchise experienced recovery with a 2.6% increase, driven by strong performance of OGx due to share gains and OUS growth for Dr. Ci Labo, partially offset by NEUTROGENA declines as retailers carry less inventory, coupled with market declines, primarily in the makeup category due to fewer use occasions driven by COVID-19 restrictions and SKU rationalization.

As consumers continue to focus on products related to personal health and hygiene, Oral Care grew by 12% on continued growth of LISTERINE mouthwash due to new flavor and product innovations and the increased demand globally related to COVID-19. Wound Care grew 12.2%, primarily due to strong performance across NEOSPORIN and BAND-AID brand adhesive bandages in the U.S. and Asia Pacific. In the baby franchise, we saw AVEENO baby strength, offset by our planned SKU rationalization program, primarily outside the U.S.

Moving on to our Pharmaceutical segment. Worldwide Pharmaceutical sales of $12.3 billion grew 14.6%, enabled by strength in all regions, with U.S. sales increasing by 15.3% and OUS sales increasing by 13.5%. The business realized double-digit growth in 8 key products across our portfolio, supporting growth in all therapeutic areas except for cardiovascular metabolism, other, which experienced a decline of 1%, primarily driven by continued biosimilar competition for PROCRIT. Our strong portfolio of products and commercial capabilities has enabled us to deliver our ninth consecutive year of global adjusted operational growth at above-market levels.

Our oncology portfolio delivered another robust quarter with worldwide growth of 23.7%. DARZALEX continued its strong performance, growing 49%, led by share gains globally with the U.S. market share up about 4 points across all lines of therapy. Furthermore, the U.S. and European markets continue to exhibit increased adoption of the subcutaneous formulation launched in the second quarter as feedback continues to be very positive on the ease and reduced time to administer the new formulation. Also, we continue to advance the DARZALEX innovation pipeline with the recent U.S. approval of DARZALEX FASPRO for the treatment of patients with newly diagnosed light chain amyloidosis.

IMBRUVICA grew 25.3% globally, mainly driven by market growth and our strong leadership position in all key indications. We continue to progress the development of IMBRUVICA to further differentiate this BTK inhibitor, as evidenced by the robust data presentation at the American Society of Hematology Conference in December.

ERLEADA continued its strong growth momentum with sales of just over $240 million in the quarter, driven by market share and penetration gains, especially in the metastatic indication. Our immunology therapeutic area delivered global sales growth of 15.3%, driven by strong double-digit performance of STELARA and TREMFYA. STELARA grew 30.3%, driven by global demand increase in Crohn’s Disease with over a 5-point share increase in the U.S. and continued growth in ulcerative colitis. TREMFYA grew 39.3% and is up about 3 points of share from the fourth quarter of 2019 in the psoriasis market in U.S. TREMFYA continues to strengthen its leadership position as the most prescribed IL-23 inhibitor for patients worldwide through its differentiated data package in both, psoriasis and psoriatic arthritis. We also continued to advance TREMFYA’s pipeline as evidenced by Phase 2 Crohn’s Disease data that was presented earlier this year.

In neuroscience, our paliperidone long-acting portfolio performed well, growing 9%, driven by market and share growth due to increased new patient starts and strong persistency. In 2020, we filed submissions in the U.S. and EU for paliperidone palmitate six-month formulation for the treatment of adults diagnosed with schizophrenia. And if approved, it will be the first and only long-acting injectable medication with a twice-yearly dosing regimen.

Our total pulmonary hypertension portfolio achieved strong growth of 37.4% with OPSUMIT growth of 36.7% and UPTRAVI growth of 44.1%, both driven by market penetration and share growth, as well as a onetime benefit of about 10 points each, resulting from the U.S. distributor model change we communicated in Q4 2019.

I’ll now turn your attention to the Medical Devices segment. Worldwide Medical Devices sales were $6.6 billion, declining 2.2%. Excluding the net impact of acquisitions and divestitures, primarily the divestiture of ASP, adjusted operational sales decline was 1.5% worldwide.

Onetime items positively impacted the current quarter by about 200 basis points. The net benefit from these onetime items is comprised of the benefit of the extra shipping days associated with the 53rd week, partially offset by the anticipated inventory contractions in China across our portfolio, and in our U.S. contact lens business, as communicated last quarter. Adjusting for the impact of these onetime items, Q4 results were in line with Q3 2020 performance.

COVID-19 remains a dynamic variable within the medical device market. In Q4, COVID-19 cases and hospitalizations reached their highest levels in certain parts of the world while cases remain relatively stable in others. This did lead to some softening in recovery trends late in the quarter. However, impacts varied across geographies and procedure types.

Looking geographically, China, where COVID-19 cases have continued to remain more stable, delivered double-digit growth within the quarter. Excluding the benefit of the additional shipping days, the U.S. declined low single digits, due to COVID-19-related restrictions occurring late in the quarter. Sales also declined in Europe, where some of the strictest restrictions were deployed to curb the increases in COVID-19 cases.

As we have noted previously, health care systems continue to demonstrate their resiliency and dedication to treating both, COVID-19 and non-COVID-19 patients, resulting in significantly less disruption during this recent surge of cases versus the impact seen earlier this year.

Interventional Solutions continue to demonstrate strong performance, delivering another quarter of double-digit growth. Electrophysiology grew 12.7% globally led by market recovery and share gains from new products. CERENOVUS returned to double-digit growth with strong sales in China. Worldwide orthopedics declined 5.3% versus prior year, driven by the negative impact of COVID-19 where procedures deem to be more elective in nature. Worldwide trauma delivered growth of 3.6% globally. U.S. growth of 10% for the quarter reflects market recovery as well as success of our new products, such as the cannulated compression headless screws.

Declines of about 6% outside the U.S. reflects slower procedural volumes due to COVID-19 restrictions as well as contractions in inventory in China worth around 400 basis points. Worldwide hips declined 2.7%, primarily due to the impact of COVID-19 on the market. U.S. declined 0.7% versus prior year and continues to benefit from our leadership position in an interior approach and strong demand for the active stem and enabling technologies, helping to partially offset the negative COVID-19 impact.

We continue to introduce innovation in this space, and in December, we entered the modular dual mobility market with the first implant of PINNACLE dual mobility, which is planned for a full U.S. market launch this year. These declined 13.9% globally as we continue to see procedures in this space highly impacted by COVID-19, especially revision procedures, where we have a higher share than primary. The 20.6% decline outside of the U.S. reflects the impacts of COVID-19 on procedures, especially in markets like the UK and India, where we hold higher share positions.

We are very excited about the FDA clearance of our VELYS orthopedic robotic system and bringing this to the U.S. market in 2021. The combination of the differentiated robotic system with our ATTUNE knee platform are expected to drive enhanced performance in this segment.

Worldwide decline in spine of 7.1% reflects the impact of COVID-19 on the market as well as inventory reductions in China impacting global performance by about 350 basis points. Offsetting this decline is the growth we continue to see from the success of recent launches of new products such as SYMPHONY and CONDUIT. For the quarter, U.S. price remained consistent with historical levels, down low single digits.

Moving to the results for the surgery business. Advanced surgery returned to growth with a 2% increase versus prior year, led by strong performance in U.S. biosurgery, which grew 12.1% in the quarter. U.S. biosurgery growth is due to the strength of SURGIFLO and the continued recovery from the previously disclosed 2019 stopped shipment.

Endocutters delivered 1.6% growth, mainly driven by the success of new products in China, offsetting impacts from COVID-19. Energy declined by 3.1%, reflecting the negative impact of COVID-19 and competitive pressures in the U.S., partially offset by the strength of new products outside the U.S. This month, we received FDA 510(k) clearances for both, the ENSEAL X1 Curved and Straight Jaw Tissue Sealer instruments, which will further strengthen our portfolio of advanced energy devices.

Global wound closure grew by 1.5% through the strength of STRATAFIX barbed suture and PRINEO topical skin adhesive products in both, the U.S. and OUS markets. Inventory dynamics in the quarter added about 350 basis points to the U.S. growth of 8.5% and negatively impacted the OUS decline of 2.9% by about 150 basis points.

The vision business declined 6.6% globally. U.S. contact lens declined 7.1%. However, after adjusting for the impact of both, the additional shipping days this quarter and the impact of the anticipated channel inventory correction communicated last quarter, worth about 9 points, the underlying U.S. contact lens business grew and continues to deliver competitive performance. While surgical vision declined 10.1% globally, this represents an improvement from Q3 where the business declined 16.4% with the most notable improvement in the U.S. This improvement is due to both, improvement in the cataract and refractive markets as well as new products like TECNIS Toric II IOL for astigmatism.

Now, regarding our consolidated statement of earnings for the fourth quarter of 2020, please direct your attention to the box section of the schedule. You will see we have provided our earnings adjusted to exclude intangible amortization expense and special items. As reported earlier, our adjusted EPS of $1.86 reflects a reported decrease of 1.1% and an operational decrease of 3.2%.

I’d like to now highlight a few noteworthy items that have changed on the statement of earnings compared to the same quarter last year. Cost of products sold delevered slightly, primarily driven by COVID-19 period costs and fixed cost, impacting the medical device business, partially offset by favorable enterprise portfolio mix and portfolio mix within the Pharmaceutical business. Selling, marketing and administrative margins improved for the quarter as a result of favorable segment mix and expense leveraging in the Pharmaceutical and consumer businesses, partially offset by the negative COVID-19 impact on Medical Devices sales.

We continue to invest in research and development at competitive levels, investing 17.9% of sales this quarter. This was higher than the fourth quarter of 2019 by 230 basis points, driven by portfolio progression, including the COVID-19 vaccine in the Pharmaceutical business.

The other income and expense line showed net expense of $2.4 billion in the fourth quarter of 2020 compared to net expense of $16 million last year. This was primarily driven by higher litigation expenses related to a Missouri Supreme Court verdict on talc in the fourth quarter of 2020, which was previously disclosed in our November 3 8-K filing and we intend to seek review of that decision by the United States Supreme Court.

Regarding taxes in the quarter, our effective tax rate decreased from 4.9% in the fourth quarter of 2019 to a 5.5% benefit in the fourth quarter of 2020. This decline was primarily driven by the tax benefit associated with the fourth quarter 2020 litigation expenses. Excluding special items, the effective tax rate was 11.4% versus 10.7% in the same period last year. I encourage you to review our 10-K for further details on specific tax matters.

Let’s now look at adjusted income before tax by segment. In the fourth quarter of 2020, our adjusted income before tax for the enterprise as a percentage of sales decreased from 27.1% to 24.9%, primarily driven by the COVID-19 impact this quarter.

The following are the main drivers of adjusted income before tax by segment. Medical Devices declined by 900 basis points, driven by COVID-19 impacts on the business, including fixed cost deleveraging associated with sales declines. Consumer margins improved by 430 basis points, primarily driven by portfolio and investment optimization, including execution of our SKU rationalization program. The decline in Pharmaceutical margins of 90 basis points was primarily driven by investment in R&D associated with portfolio progression, including the COVID-19 vaccine.

This slide provides our full year consolidated statement of earnings. Please direct your attention to the box section at the bottom of the schedule, where again, you will see we have provided our earnings adjusted to exclude intangible amortization expense and special items.

As reported today, our full year 2020 adjusted EPS of $8.03 reflects a reported decrease of 7.5% and an operational decrease of 7.8%. The decline is primarily related to COVID-19 impacts realized predominantly in our medical device business, along with increased R&D investment, including the investment associated with our COVID-19 vaccine candidate.

Moving to the next slide. Our full year 2020 adjusted income before tax for the enterprise decreased by 360 basis points versus 2019. Looking at the adjusted pretax income by segment, Medical Devices declined from 35.4% in the previous year to 17%, primarily driven by COVID-19 impacts on the business, including fixed cost deleveraging associated with sales declines. 2019 also includes approximately $2 billion related to the divestiture of the Advanced Sterilization Products business. Pharmaceutical margins improved by 200 basis points to 42%, driven by favorable product mix and sales, marketing and administrative expense leveraging. Consumer margins improved by 240 basis points to 23.8% driven by portfolio and investment optimization, including the execution of our SKU rationalization program.

Moving on to important developments. For your reference, here is a slide summarizing notable developments occurring in the fourth quarter, some of which were mentioned in my comments. For your planning purposes, we plan to host a business review, featuring our Pharmaceutical business on November 18th of this year. The format and location will be announced at a later date, but we hope that you’re able to join us for this event, where we look forward to sharing the details about our robust pipeline and differentiated capabilities, that gives us the confidence in our ability to sustain growth in Pharmaceuticals at above-market levels.

That concludes the sales and P&L highlights for Johnson & Johnson’s fourth quarter and full year 2020. I’m now pleased to turn the call over to Joe Wolk.

Joe Wolk

Thank you, Chris, and thanks to everyone joining today’s call. As you heard, Johnson & Johnson’s results reflect the strength and resilience of an agile, broad-based business predicated on innovation, despite unique challenges throughout 2020. The unwavering commitment of our 135,000 global colleagues was on full display, delivering trusted, life-saving, life-enhancing products to patients and consumers around the world. Their efforts resulted in sound shareholder returns while advancing value-creating opportunities that benefit all of our stakeholders now and over the long term.

Alex stated on this call and really throughout 2020 that Johnson & Johnson is built for times like this. Our disciplined, long-term focus yields a financial strength that affords us the ability to quickly act to address the COVID-19 pandemic in many ways, most notably on our ongoing vaccine development, but to also continue investing in innovative solutions to better the future of health care even when short-term uncertainty exists. I am very pleased today to share our financial guidance for 2021, which reflects these principles. But, first, let me review our cash position and capital allocation priorities.

We generated free cash flow for the year of $20 billion, surpassing last year’s record high. We did benefit by having our fiscal year-end lapse into 2021, as Chris noted, and we are now planning for a payment related to the anticipated final opioid litigation agreement in principal in 2021 versus the previous planned 2020 payment. In terms of our cash position at the end of 2020, we had approximately $10 billion of net debt, comprised of approximately $25 billion of cash and marketable securities and approximately $35 billion of debt.

One element of our business that we’re particularly proud of that despite the challenges of 2020 offered, we maintained our long-term approach to drive growth and value creation across the enterprise. From an innovation standpoint, the development of a safe and effective COVID-19 vaccine was certainly a top priority throughout the year. Yet, as I said earlier, we continued to make other strategic investments that fortified our pipeline and further enhanced our competitive advantage even during the pandemic. Our level of R&D investment reached an all-time high of $12.1 billion, $800 million more than our 2019 R&D investment.

On the transaction front, we continue to evaluate opportunities that strategically complement our portfolio and where our scientific expertise or commercial capabilities can create unique value. Over the course of 2020, we invested over $7 billion in such opportunities.

As discussed on our third quarter earnings call in October, we acquired Momenta Pharmaceuticals and a lead therapeutic candidate, nipocalimab, which is in Phase 2 and Phase 3 clinical development for the treatment of rare autoantibody-driven diseases. We believe nipocalimab encompasses a pipeline and a product opportunity that can treat a broad range of devastating autoantibody-driven diseases.

In December, we expanded our retina pipeline by acquiring the rights to Hemera Biosciences investigational gene therapy, HMR59, a onetime outpatient intravitreal injection to help preserve vision in patients with geographic atrophy, a severe form of age-related macular degeneration, where currently, there are no other approved therapies. And as shareholders in Johnson & Johnson have come to expect, we continue to prioritize our dividend by announcing last April a 6.3% increase. This translated in returning $10.5 billion to investors in 2020, approximately 50% of our free cash flow.

Let’s now turn to our full year 2021 guidance. Given our full year 2020 performance in this unprecedented environment and the underlying strength of our broad-based business, we are well positioned to continue delivering long-term value to our stakeholders. We continue to monitor and work with health care systems around the globe as they balance surges in COVID-19 cases with treatment for non-COVID-19 patients.

I would be remiss if I didn’t acknowledge the tremendous efforts of health care providers around the world that have society in a much better place today with improved treatment protocols and resource allocation compared to the start of the pandemic. We are also encouraged by the recent availability of COVID-19 vaccines that will provide added reassurance to people in need of medical procedures.

From a macroeconomic perspective, our outlook assumes stabilizing employment levels and a reduction in social restrictions as the year progresses. From a legislative standpoint, we are not assuming significant changes in current tax policy, and consistent with the past four years in our Pharmaceuticals business, we expect net price decreases at similar levels. We will continue to focus on providing access to more patients for our innovative products, resulting in growth being volume-driven.

So, let’s get into the details for full year 2021 guidance for you to consider in updating your models. I’d like to note upfront that our guidance excludes the financial impact from the potential distribution of our COVID-19 vaccine candidate. As Alex noted, we remain committed to provide a safe and effective vaccine. Being in the final stages of a robust 45,000-person study, analytics will be completed, and we plan to report out the results by early next week. Therefore, it would be premature to speculate. We will let the science play out. Once we have the data, obtain regulatory authorization and finalize agreements to supply, we will provide financial updates, as warranted, likely during our first quarter earnings call in April.

Starting with sales. We expect adjusted operational sales growth for the full year 2021 of between 8.0% and 9.5%. This adjusted operational sales growth is on a constant currency basis, reflecting how we manage our business performance. We estimate the negative impact from net acquisitions and divestitures of approximately 50 basis points and as such are comfortable with your models reflecting operational sales growth in the range of 7.5% to 9.0%, or $88.8 billion to $90.0 billion.

As you know, we do not predict the impact of currency movement. But for some context, utilizing the euro spot rate relative to the U.S. dollar as of last week at $1.21, there is an estimated positive impact of foreign currency translation of approximately 200 basis points, resulting in an estimated reported sales growth of between 9.5% and 11.0% or 10.3% at the midpoint compared to 2020 or $90.5 billion to $91.7 billion.

Let’s now turn to earnings per share. This slide illustrates the components of our 2021 EPS guidance. Roughly half of our EPS growth is attributed to the robust operational sales growth and the other half is attributable to strong net income margin improvement, driven by expected operating margin improvement of more than 200 basis points versus 2020. The medical device COVID-19 recovery and other cost improvement initiatives are planned to more than offset our continued investment to accelerate our business and further strengthen our pipeline of new products for the long term.

As a reminder, included in our 2021 guidance is the dilution from the recent acquisition of Momenta, negatively impacting EPS by about $0.15 or $0.10 versus 2020. Considering these items, results in adjusted operational EPS in a range of $9.25 to $9.45 or $9.35 at the midpoint, reflecting a 16.4% year-over-year increase. While not predicting the impact of currency movements, assuming recent exchange rates, our reported adjusted EPS would be positively impacted by approximately $0.15 per share, resulting in adjusted reported earnings per share of $9.50 at the midpoint, reflecting growth of 18.3% versus the prior year.

Continuing with EPS guidance. This slide provides a summary of what I just shared along with some additional P&L items, to give you more insight into the drivers of our full year guidance. Beginning with other income and expense, the line on the P&L where we record royalty income as well as gains and losses related to the items such as investments by our Johnson & Johnson Development Corporation, litigation and write-offs. As I discussed on previous earnings calls, we will continue to be rigorous regarding portfolio management, but going forward, we will not include the impact of significant divestiture gains in adjusted EPS. Given those considerations, we would be comfortable with your models for 2021, reflecting net other income and expense, excluding special items, as net income ranging from between $600 million and $700 million.

We continue to actively evaluate external value-creating opportunities, but for purposes of your financial models, we are not assuming any major acquisitions or other major uses of cash at this time. Therefore, we are comfortable with you modeling net interest expense of between $150 million and $250 million. We are also projecting a higher effective tax rate for 2021 in the range of 16.5% to 17.5% or a midpoint of 17% due to beneficial onetime items in 2020 related to the closeout of audits in several jurisdictions that will not repeat in 2021.

Let me spend a few minutes providing some qualitative context about 2021, although not intended to specifically provide segment or quarterly guidance. Given variability that occurred due primarily to COVID-related dynamics, this slide, while not to scale and meant to be illustrative, offers some perspectives on the quarterly phasing across our businesses. From a sales perspective, as Chris noted earlier, we benefited from additional selling days in 2020 that will not repeat in 2021. That should be applied to both, the full year and the fourth quarter for the enterprise and by segment.

I’ll address each segment starting with Pharmaceuticals, where we anticipate another strong year of above-market growth. Throughout 2020, we saw COVID-19-driven fluctuations, and most pronounced was the first quarter when, as we noted, we benefited from longer script durations. We continue to invest in COVID-19 vaccine development, impacting the first quarter while we pursue authorization. For 2021, we expect more balanced quarter-to-quarter growth. Lastly, while we expect to continue to face pricing pressures and the ongoing negative impact of generic and biosimilar competition, we do not expect any significant new generic or biosimilar entrants in 2021.

Turning to our Medical Device segment. As mentioned earlier, we observed instances of nonemergency procedure postponements late in the fourth quarter, but health care systems continue to meet the needs of both, COVID and non-COVID patients, resulting in less COVID-19 market disruption as we progressed through 2020. While macro market dynamics such as vaccine deployment, unemployment and health care coverage remain fluid, we are anticipating some moderate procedural disruption to carry into the first quarter but expect continued medical device market improvement throughout 2021 fluctuating by quarter.

As you heard during our Medical Device update in November, our core platforms continue to strengthen, driven by enhanced execution and improved cadence of innovation and filling critical portfolio gaps, including and most notably, advancing our future digital surgery offerings. We believe the combination of the expected market recovery and the actions taken to strengthen our device business positions us to drive revenue growth each quarter versus 2020 with some continued headwinds due to COVID-19 tempering growth in the first quarter and the highest growth rate expected in the second quarter, given the significant market disruption realized in the second quarter of 2020.

Our Consumer Health segment yielded solid performance throughout the pandemic, resulting in above-market growth. But as noted on our third quarter earnings call, that performance is likely to yield negative COVID-related sales comparisons in the first quarter of 2021, primarily in over-the-counter products. We also plan that our continued SKU rationalization program will have a negative impact on sales in the first half of 2021 while we continue progressing our margin expansion. For the second half, we would anticipate more normalized growth as consumers return to more typical usage patterns for products in areas like Skin Health and Beauty. Therefore, although not linear, for the full year, we anticipate growing competitively with the markets in which we compete.

We are confident in the strength of our broad-based business and its underlying fundamentals. We are positioned to deliver meaningful value to all of our stakeholders, not just in 2021, but over the long term.

Alex and I look forward to addressing your questions. So, I’m now pleased to turn the call back over to Chris to initiate the Q&A session. Chris?

Chris DelOrefice

Thank you, Joe. We will now move to the Q&A portion of the webcast. Operator, can you please provide instructions for those on the line wishing to ask a question?

Question-and-Answer Session

Operator

[Operator Instructions] And your first question is from Terence Flynn with Goldman Sachs.

Terence Flynn

Hi. Good morning. Thanks again for all the work you’re doing to combat the pandemic and looking forward to the vaccine data next week. I was just wondering, with respect to the vaccine trial, if you can remind us what percentage of participants were enrolled in South Africa and Brazil, and if you’re gathering sequencing data from these participants that become infected. And when you report the data, are you going to break out results by geography? And hence, will we have any insight in terms of the vaccine efficacy against some of these new variants? Thank you.

Alex Gorsky

Hey Terence, this is Alex. Thank you very much for your question. Look, maybe before I answer this — your question, let me just back up for a higher level. And once again, note, what I think has just been the tremendous contributions and performance of our 150,000 approximate associates around the world, 50,000 of whom have been going to work every day in our factories and our laboratories to ensure the products and services could continue to flow to patients and hospital systems around the world, let alone the important work that we’re doing on the vaccine.

Next, I also just think it’s very important to reflect on the tremendous impact that COVID-19 has had around the world. You’ve heard some of the numbers that we mentioned earlier today, whether it’s almost 100 million cases around the world, let alone 2 million deaths globally, or right here in the United States, almost 25 million people and over 400,000 deaths, that’s taken a tremendous cost on certainly families, individuals, businesses, our economy on just so many different aspects of our life that all the more important for us to be doing everything we can to make a difference during this pandemic.

Last but not least, I’m just very proud of the performance that we had, not only in the fourth quarter but throughout 2020. If you look at the various segments, in almost each of our sectors, all of our major platforms, what you saw is us ending the year in a better position than where we started. And that wasn’t only for what I would call the near-term financial performance where we saw things like market share gains and position improvements, but also if you look at the investment that we made in research and development, in sales and marketing, preparing for the future, not only 2021, but that and beyond, again, we think we’re well-positioned and stronger as we finish the year than even when we began.

Now, getting back to your specific question regarding the breakouts, we’re going to have much more information in the coming days. We think it’s very important to follow the data, to follow the science. At that time, we think it will be more appropriate to provide you with all of the various cuts of the data that we anticipate having. Consistent with the statements that we made from the very beginning, we want to ensure that we’ve got a very robust program, not only geographically, but also by ethnicity, gender as well as a number of other different parameters, all as part of an effort to give us the best possible understanding of the efficacy and safety profile of our vaccine. So, stay tuned. As Joe alluded to in his earlier comments, and Chris, we expect to have these results in the coming days. And our scientists, Dr. Mathai Mammen, Dr. Paul Stoffels and others will be providing much more detail once we have those results.

Operator

Your next question comes from Larry Biegelsen with Wells Fargo.

Larry Biegelsen

One more, one on the vaccine and then one financial question. So, Alex or Joe, I heard Joe’s comments on CNBC about your expectations for the vaccine to be robust. What do you think you need to show to be competitive? Is 70% a good floor? And Joe, do you still expect to produce 1 billion doses in 2021? And just lastly, I know you said that you’re not going to give any financial guidance until I think your next call. But since the data is coming next week, any color on pricing and margins during and after the pandemic? Thanks, guys.

Alex Gorsky

Hey Larry, thank you very much for your question. As I mentioned earlier, I think it would be inappropriate for us to speculate in any significant way, given the proximity that we are today versus when we expect the results. What we said from the very beginning is that we put a lot of work and thought and very strong science and review into the selection of our lead candidate. I think, the Phase 1 and 2a results, particularly those that were recently published, we are hopeful that’s a good precursor to the kind of efficacy and safety that we’ll see in larger population, of course, until we see this final data, we won’t know for certain. But look, we remain optimistic, and we’re going to remain very diligent as we go through this final review. I’ll hand it over to Joe to take the second part of that question.

Joe Wolk

Sure. Good morning, Larry. And thanks for the question. I would say with respect to supply, consistent with the comments that were made earlier, we intend to meet all of the firm order commitments that we have, whether that be to the United States, to the European Union or to developing countries through the Gavi organization. And right now, we’re well on track to do that. As Alex alluded to, there is still some fluidity with respect to timelines. And I think what we’re seeing happening with a little bit of confusion is people are trying to parse this down into weeks. I think, the definitive statement here is that we are very comfortable in meeting our commitments to those respective countries or organizations that I just outlined.

In terms of financial implications and pricing, as you can imagine, once countries get a chance to see the data, we’re in active negotiations for other countries and other organizations, and the volume will impact the selling price. So, it’s somewhat of a fluid situation, and that’s why we’re kind of projecting or leading folks to think about the April first quarter earnings call as a good time when many of those pieces will be in place, and we can give you some credible information to bank on for the balance of 2021.

Operator

Your next question comes from David Lewis with Morgan Stanley.

David Lewis

I guess just — maybe just two quick ones here for me. The one would just be just in general, as you think about new variants in the marketplace and the need for a booster. I wonder if you could just comment on number one, when can we expect the dual dose data, and what are your thoughts about the booster relative to the mRNA-based platforms? And then, I guess, just on earnings strength for next year, ’21, Joe, just 200 basis points of year-over-year margin expansion, just seems like given the earnings upside relative to consensus estimates, you probably need a margin number that is maybe closer to 300 basis points of year-on-year upside versus 200. So just give us any sense of what’s driving margin strength, some of that’s medical device recovery. I’m sure some of that’s pharma strength as well. But, it’d be super helpful, just give us a sense of the earnings momentum into ’21. Thanks so much.

Alex Gorsky

Hey David, this is Alex. I’ll take the first part and then let Joe take the second one. Look, we — as I mentioned earlier, we’re continuing to pull together all of our data. We’re enrolling, as we speak, in the dual dose information. We would expect that — to have that in the back end of this year. And again, as we — just as we try to be very transparent and very thorough in the disclosure that we’re releasing, we certainly will plan to follow that course with that trial as well. And again, we’ll get out information as soon as we can.

Regarding some of the variants, obviously, we’re watching that closely, based upon some of the regional, the geographical differences that we’ve seen. And look, our scientists are already anticipating, as you heard from some of the other companies, about what are potential scenarios to ensure that we’re prepared. But look, I think, it starts with taking a look at the data that we currently have that we should have shortly. And I think Dr. Paul Stoffels and Dr. Mathai Mammen, once we have that, will be able to give a much more comprehensive review on exactly how we think our vaccine will work against the current strains and variants and our plans for the future. Joe?

Joe Wolk

Good morning, David. With respect to kind of the earnings outlook and specifically, the operating margins, you’re correct. And not to get cute, but the words were actually greater than 200 basis points. So, that could gravitate upward. We certainly want to keep the flexibility that we’ve had even during 2021 and all that uncertainty to continue to invest in innovative ideas that really fortify, not just this year, but well beyond.

In terms of some of the programs we have that are improving our operating margins, I’d point you to this consumer SKU rationalization. That is certainly something that will have an impact on consumer sales in the first half of the year, but again, with this objective of improving profit margins, and that team has done a great job under Thibaut’s leadership with respect to improving the margin profile over the last two years.

You may also recall a few years back made significant investments in our supply chain infrastructure. Some of those are starting to pay off in 2021 as well. And then, like it or not, we are working differently, and there are efficiencies that correlate to some of this working differently. I’m not suggesting that we found a steady state in terms of the balance between virtual work and work in the office, but there are some efficiencies that are being realized that I think will actually sustain long term as we move forward. So, those are some of the factors that are going into our bullish call of above 200 basis points margin improvement.

Operator

Next question is from Louise Chen with Cantor Fitzgerald.

Louise Chen

So, just curious if you could comment on the durability of your vaccine versus the other vaccines that are in development or at least your goals for durability, you did highlight that you your Phase 1/2 data. And the second question is just as Biden rolls out on his health care policies, are there any big moving parts that you see as potential pushes and pulls to the health care industry? Thank you.

Alex Gorsky

Hey Louise, Alex. Thanks again for your question. Regarding durability, again, we’re going to have to see how some of the early data in some of the preclinical work that we have done plays out in the actual large-scale trials. We’re certainly hopeful that you’re going to see a durable and a sustainable and patent response, particularly from our vector approach. We have seen that in other programs that we run. So, we’re hopeful that we’ll see it here, but we would expect that to play out. We are pleased with not only the antibody response that we saw but also some of the cellular level response that would be in T cells. But again, more information will be available once we have our other final results.

Secondly, more broadly, about health care, I do think that — and we do feel that COVID-19 has had a very profound effect on health care systems, both near term and short — and longer term. I think, in the near term, what we’ve learned is frankly the importance of innovation and science. And if you reflect back on where we were, just 11 or 12 months ago at the beginning of COVID-19 and where we are now in the number, not only of very innovative vaccine candidates, but therapeutics and the differences that they made. If you take a look at the way hospital protocols very rapidly and quickly started to using data sciences and information to better understand what was going on with patients entering those facilities, how they should be treated, what led to better outcomes, how that’s impacted the reduction in morbidity, I think clearly, another example.

Third, we’ve seen a rapid expansion in telehealth, and that’s in primary care offices but also specialty offices. The way that companies like ours actually communicate and engage and educate physicians and health care systems, we would see that lasting for some time as well. And clearly, on the public health side, we think that’s also a very important dynamic for us to consider going forward. I mean, I think it’s clear from this that the world now has a much better understanding of the importance of well-established, well-funded global public health programs, without which we’re at significant risk around the world, whether it’s our economies, society, just at a number of different levels. So, those are perhaps some of the longer term trends.

And last but not least, I’d like to do a — just a shout out for the partnership and collaboration that we’ve seen with not only within industry and across industry but also with regulators around the world. And it’s certainly our hope that we can take some of that and apply it to other advancements, whether it’s cures for cancer, neuroscience, other conditions. If we can take some of those same paradigms and accelerations and apply them there, that would be great news, not only for patients, certainly in health care systems, but for the industry as well.

Joe Wolk

Hey Louise, maybe just one other comment to build upon Alex’s commentary is that you’ve referenced towards the end of your question about the new administration and what kind of policies they may have around health care. What I would say is we’ve been around for 135 years. It’s I think 24 different administrations from both, Republican and Democrat. We’re going to continue to do what we do best, and that’s to innovate. And if I look at our pharmaceutical portfolio, the great performance that they delivered in 2020 was once again met with, for the fourth consecutive year, price decreases overall in the portfolio. So, we’re seeing the benefit of innovation, whether it be for the COVID-19 vaccine or other solutions in immunology, oncology, pulmonary hypertension and neuroscience. And so, that’s what we’re going to be focused on.

And by the way, Louise, I just got a comment. You did a really nice job on the news program this morning. That was outstanding work by you.

Alex Gorsky

Hey Louise, I might just add one other point and that is, we actually look forward to working with the new administration on issues related to health care. Clearly, the pandemic we feel will shape the perspective in terms of the prioritization around access, around innovation, and frankly, using this as an opportunity to improve the overall health care system.

Operator

Your next question is from Chris Schott with JP Morgan.

Chris Schott

Just on 2021 device sales, can you just help us quantify or provide more color around how much of an impact COVID will still be having on sales, but what you consider to be I guess normalized levels? I’m just trying to get a sense of how close to normalized is 2021 as we maybe think about 2022 and beyond? Is there another step-up in sales we need to be thinking about in that time frame? My second quick one was just on STELARA. The product is obviously generating very healthy growth, despite increased competition in the psoriasis space. Maybe a little bit more color there in terms of the sustainability of growth you see as we just think about that franchise evolving over time? Thank you.

Alex Gorsky

Chris, look, overall, we remain very confident in the long-term prospects around the medical device market. And I think we saw very good signs of that actually over the course of 2020, where we saw the medical device market drop anywhere from 30% to up to 70%, depending on which category you’re looking at, to return to mid-single-digit drops in the third quarter as we went through the rest of the year. As Joe and I believe Chris alluded to earlier in some of their commentary, we would expect see continued impact certainly in the first quarter of 2021, although the early signs, we’re encouraged by what we’re seeing in hospitals’ ability to manage through some of the current patient demands. There are certainly regions and hospitals around the world, let alone in the United States, where you see a tremendous strain on the systems. But overall, we’re seeing hospital volumes decrease no more than about 10% or 15% in areas such, for example, in the UK, a couple of other places in Europe. But overall, the resiliency and the ability of the hospital systems that continue with elective surgeries has improved quite significantly. And as you — as I’m sure you would project, if we look at second quarter, in particular, the year-on-year comparison should return.

As we look at our team’s performance and consider 2021, we’re actually looking at 2019 as more of a benchmark to — and to use that as an indicator more of what a baseline or normal would be. But again, we can — we would expect to continue to see expansion over the course of 2021. And beyond that again see a return to a market that was growing in the mid-single-digits previously, and we would expect that to continue going forward as well.

Chris DelOrefice

There was also a question about STELARA.

Alex Gorsky

Yes. Regarding STELARA, look, we remain very upbeat on the overall performance of STELARA. I mean, if you look at the performance in the fourth quarter, it was about 30% growth for the full year. We are looking at 20% growth. And what’s really important to remember about STELARA is just the diversity of indications now that we have with that compound, especially in GI conditions, where we think it’s particularly differentiated and unique, both in terms of its efficacy and now a very robust safety profile as well, based upon the years of experience. It is a competitive category. There are a number of new agents. But we also know that this is an area of significant unmet medical need, again, particularly in the Crohn’s space and the rest of the GI category. And so, we think there remains really good opportunity for us to continue to not only maintain but grow our position.

Joe Wolk

And Chris, if you look at where the growth is coming from for STELARA in recent quarters, it has been in the GI indications that Alex has noted where we’re really seeing nice growth in uptake in psoriasis is TREMFYA. You’re right, it’s a competitive market space, but we’re seeing some switches out of STELARA to TREMFYA, and then TREMFYA is picking up new scripts on its own for our psoriasis play.

Chris DelOrefice

And just for context, the share growth in Crohn’s and STELARA was over 5 points quarter-over-quarter, so seeing great progress there. Thanks, Chris. I appreciate the questions. Rob, next question, please?

Operator

Your next question comes from Joanne Wuensch with Citi.

Joanne Wuensch

Two questions in medical device land. With the VELYS approval, can you sort of give us a date on how you’re thinking about rolling that out, and whether or not those plans change in the current environment? And then, in Vision Care, there are a couple of different pushes and pulls going on, both in contact lenses as well as in vision surgery. Could you tease that out a little bit as we think about SKU rationalization versus competitive pressures?

Alex Gorsky

Sure. And good to hear from you, Joanne. Joanne, regarding VELYS, look, we were very excited about the approval with the FDA. As we were able to share with you during our Innovation Day with our Medical Device group, if we look at the flexibility, the accuracy, the reduced footprint that it provides the surgeon and surgical teams, we think that it just has tremendous potential. Again, this is a market that is still — we think has a significant opportunity for growth in terms of penetration. We also think it will be a nice complement to our ATTUNE fixed bearing cementless knee. And remember, we also have plans to expand VELYS significantly beyond just knee replacement but to other areas as well.

So, when you combine that, we think it will be very competitive. And more importantly, we think it will be a great new option for physicians, for orthopedic surgeons and ultimately for patients and their families. I’m not going to get into all of the launch plans. But, what I will tell you is the team has got an aggressive agenda lined up, and they’re completing all the other associated testing as we speak. But, we look forward to launching that over the course of 2021 and again, expanding our overall position.

Regarding Vision Care, you’re right. There are a lot of dynamics that we certainly saw in the past year, in the contact lens market, significant contraction as well as in the surgery market. We believe that our position overall in the contact lens has continued to strengthen. And we did see improvement as we went quarter-to-quarter and ended the year, and we think we’ll be well-positioned as we enter 2021. We’ve also made a number of changes regarding our surgical business. We’re excited in 2021 about the TECNIS Symfony launch with a depth of focus lens. It’s got improved near-term focus. And we also have a TECNIS Synergy IOL, a first-in-class product, combining a number of different technologies, to really deliver a great range with high contrast. We expect that in ’21. So, again, we remain very confident and optimistic about the potential overall in our Vision Care business.

Chris DelOrefice

Yes. Joanne, just a couple of small builds. In contact lens, as we have noted in prior quarter, if you remember, in the U.S., there was double-digit growth, and some of those were some of the retail dynamics as it related to inventory and stocking that you noted, adjusting for that contact lens did grow. It was worth almost 9 points. And we do view our growth is still competitive versus the market.

And then, on the surgical side, it was actually good. We did see some recovery in the market there. So, it’s good to see the trend. While we’re still declining, it’s improving sequentially, and we remain optimistic, including the innovation that Alex mentioned.

Operator

Your next question is from Matt Miksic with Credit Suisse.

Matt Miksic

So, just a couple of follow-ups on Med Devices. You’ve made some great progress in 2020, closing the gap on digital surgery and abdominal surgery, orthopedics and lung. And just curious, sort of following on to Joanne’s question around the VELYS rollout is, how to think about this — you get recovery in volumes generally in the market, in some of these end markets, and then, you’ve got sort of the benefit of these new digital surgery sort of launches. And is that — do we see that in back half of the year? Do we start to see ortho this year and Ottava maybe the following year? If you could just maybe lay out the cadence for both the top line and any investments that those entail for Med Devices, that would be super helpful.

Alex Gorsky

Sure, Matt. Thank you very much. Look, we were — I think, it’s important to put maybe perhaps some additional perspective on it. If we really go back to 2017, where I believe the growth rate of our Medical Device division was about 1.5-point, and if you look at the expansion as we went through 2019 to where it was growing at almost a 4% rate. And as we’ve articulated a number of times, our goal is to grow at or faster than the markets where we compete. We believe the markets where we compete overall in surgery and orthopedics and vision care and others, cardiovascular, are in the 4% to 5% range. And that’s the goal for our businesses. As we — of course, with 2019 — or 2020, excuse me, and the effect of COVID, that had a very significant impact. But again, here too, if we normalize out our trends for third and fourth quarter, we think that overall, those quarters were pretty consistent, down about 3.5% after you pull everything else out, and will put us on a good rate, as we mentioned earlier, over the course of 2021 and beyond.

Regarding VELYS, as I mentioned earlier, we think it does offer a number of unique advantages. We think it can enhance the surgeon’s ability to really personalize total knee arthroscopy. At the same time, it has certain features that will make it easier for use potentially in the operating room. And again, we think it’s going to be a great complement to not only our ATTUNE system, but further down the line to our hip procedures and others as well.

We do feel that the overall knee market will recover in 2021. It will take place over the course of the year as hospitals are able to continue to get their capacity back, as patients get increasingly confident. The knee market was perhaps hit more than others just because many of those procedures can be delayed, perhaps versus a hip procedure. But, we would expect that to return over the course of this year as we see the pandemic dealt with in a more effective way and things hopefully return to a more normal state. And by the way, we think the outlook for that longer term, given some of the pent-up demand that we’re likely to see, will be quite significant.

As you saw in our review back in November, we’re very excited about Ottava. We truly think it’s going to offer a next-generation digital and robotic surgery. As you just mentioned, the team made great progress over the last 12 months. As we brought the various technologies together, we continue to do the build-outs and when — we remain on track with all the time lines that we have previously committed to. And we’re confident that here too is a market that we think is very — has very low penetration, less than 5% or 10%, certainly on a global basis, more so in certain categories here in the United States. But, whether it’s penetration or the ability just to expand those kind of options to surgeons here in the United States around the world, based upon the technology that we’ll be bringing, we think it will offer significant upside on the time lines that you just mentioned.

Operator

Your next question is from Danielle Antalffy with SVB Leerink.

Danielle Antalffy

I just have a quick COVID question. And I’m sorry if I missed this, Alex. I feel like you did allude to the in response to Matt’s question. But, over the last two quarters, you had given pretty detailed numbers around the COVID impact. Is there any way you could give that for this quarter, just to get a sense of sort of what the normalized growth rate actually would have been, were it not for the COVID resurgence? Thanks so much.

Alex Gorsky

Yes. Thanks, Danielle. I can take that one. Yes, we were able to do that in Q1 because there was an early impact. And then, what we did was as we provided guidance throughout the year, we kind of gave you a range of expected impact by quarter, based on what our original guidance would have been at the beginning of the year. If you look at what we shared in Q4 ahead of this earnings, we’d anticipated that we could be anywhere from down 10% or flat versus our original thinking, which would have contemplated some growth year-over-year, plus a 53rd week. If you look at where we landed, we basically landed at the low end of that range, given some of the additional softness that the market experienced in the December timeframe where procedures were probably down more around that 10% range. So, overall, in line with expectations, but more towards the low end, given some of the surge we saw at the very end.

Operator

The last question will be coming from Bob Hopkins with Bank of America.

Bob Hopkins

Thank you very much. Just one quick one. I appreciate the comment that globally in Q4, Medical Device revenue declines were really no worse than Q3 when you adjust out the onetimers. That’s pretty impressive given the headlines. I was wondering if you could give us a sense to what happened to device growth, maybe in the United States in Q4 relative to Q3, again net of those onetimers. And also on the U.S., if we think about 2021, is it too aggressive to assume that in the back half of 2021, based on everything you’re seeing today that we might be able to approach normal levels of surgical procedure volumes in the United States? I appreciate the comments. Thank you.

Alex Gorsky

Hey Bob. Thank you very much. What we saw in North America in Q4 was it down just about — or excuse me, up about 2%. And again, there were regions around the country where we saw a differential impact. But, I think it’s fair to say that we were pleased to see the ability of the majority of systems in the United States being able to continue to provide elective procedures, even in spite of some of the later surges where we saw even more significant impacts were in Europe and LatAm during that period. And because of our stronger position in certain places in Europe that had a differential impact on us. And again, as hopefully, we see improving trends with the virus in Europe over the course of 2021, we would expect to see that return.

And so, regarding your questions on volumes in the back end, look, it’s hard to predict based upon where we currently are. As we said earlier, we think the most significant impact this year will be certainly in Q1. As we continue to deal with some of the ongoing surge, we would expect the year-on-year comparisons to change pretty significantly in Q2 and Q3. And again, assuming much improved vaccine distribution, better overall control of COVID-19, we would then expect to see volumes come back to more normalized levels as we finish the year. But obviously, there’s a lot of moving parts. There’s a lot of assumptions, a lot of dynamics that we’ll have to watch closely. But, our current plans would take those kind of projections into consideration.

Chris DelOrefice

Great. Thanks, Bob. I appreciate the question. Thanks everyone for your questions and your continued interest in our Company. Apologies to those who we couldn’t get to because of time, but don’t hesitate to reach out to the Investor Relations team, as needed. I’ll now turn the call back to Alex for some brief closing remarks.

Alex Gorsky

Well, thank you everyone for your comments, for your questions and for your ongoing interest, trust and confidence in Johnson & Johnson. It’s likely an overused term at this point, but 2020 was a remarkable year on just so many different fronts. And I want to again end where I started by acknowledging the tremendous toll that this has taken on patients, on families, on the hospital systems around the world, but also give credit to health care systems and our employees who’ve worked so hard to continue to support the same, through this challenging period. We’re proud of our performance. We think we’re positioned very well as we embark on 2021, and we look forward to keeping you updated as we go through the year and gain more information and insights. Thank you very much, everybody.

Operator

This concludes today’s Johnson & Johnson’s Fourth Quarter 2020 Earnings Conference Call. You may now disconnect.

Putin’s Cleveland law firm, Jones Day, has closed its Moscow offices and immigrated the Russian who led it to D.C.

CLEVELAND, OH – If AdvanceOhio president Chris Quinn thinks readers are going to pay $100 a year to read cleveland.com, his reporters had better learn to find stories like those in EJBNEWS.  No intelligent person will pay to read plagiarized government news releases and paid client driven content.

Squire Patton & Boggs global managing partner and attorney Fred Nance must not believe fat meat is greasy.  Seven figure earnings and a high-rolling global lifestyle from his Moreland Hills palace must have blinded Fred to the tea leave writings on the “Foreign Agents Registration Act” wall.  The Russia shit is over.

Close the Moscow office like managing partner Steve Brogan at Jones Day did in December 2019.  Disconnect all ties with Russian government officials and the government’s clients.  Come home and the face the Logan Act, Espionage Act and Foreign Agents Registration Act music.  The traitors have been exposed over the past four years.

No more Rosneft money.  No more Gazprom Bank money.  Don’t go meet with Putin for his annual conference with over 600 U.S. corporations in St. Petersburg, Russia in 2021.  Remember?  FBI agents raided Michael Cohen’s office in Squire Patton & Boggs’ New York office in April 2018.

 

Representing the Russian Federation and representing Diebold while ex-chairman Walden O’Dell is selling electronic voting equipment to the nation’s election’s board is wrong.  Suing California prosecutors to keep election security flaws a secret, while representing the Kremlin as an unregistered agent, well gosh darn boys and girls.  Here in America that’s a crime which makes the perpetrators … traitors.

It’s also further evidence of a conflict in national security interests when Putin’s law firms are behind suing Rutger’s University to take down a website that published all of Diebold’s email.  I have the dastardly documents and shared them with United States Representative Marcia Fudge; who shared them with Homeland Security.  What other election secrets, violations of federal felony laws, did the two firm’s lawyers conceal by not reporting as the unregistered agents of foreign governments?

Former White House Counsel Don McGahn was a partner in the law firm of Jones Day that represents Vladmir Putin and Goldman Sachs. While in the Trump administration one of McGahn’s duties was to help the president select Supreme Court justices. This is while the employer he returned to in March 2019 after leaving Trump continued to represent Vladmir Putin. So now McGahn’s back with Jones Day and free to communicate with the law firm’s global network of 2500 attorneys in nations like Russia without his firm ever registering as a foreign agent of the Russian Federation while he worked in the White House around the nation’s defense secrets. Putin’s law firm’s partner left the U.S. with a Supreme Court justice or two in place for life.

The timing may be coincidental, but after Fudge’s congressional hearing and subpoena to the nation’s electronic voting equipment presidents, Jones Day’s managing parter, Brogan, announced the closing of the law firm’s Moscow office.  Even Jones Day’s “Moscow” office web page “does not exist.”

Moscow “partner” and Russian citizen Vladimir Lechtman‘s been “Linked In” repackaged as “more American” than Russian with three years of legal training at the University of Texas at Austin.  He’s now relocated to Washington, D.C. on some kind of green card scheme.

The Russian alien – who graduated law school in Austin at the University of Texas in 1983 on a student visa – is now made to look like a legal citizen after spending 30 years in his homeland handling Jones Day “unregistered” legal work for the Russian Federation and its business entities.   The miracle of one year citizenship and enrollment in the Washington, D.C. Bar Association would have to be rigged at the highest levels for Lechtman, Putin’s lead Jones Day attorney, to be working around the corner from the White House at 51 Louisiana Avenue as “of counsel.”  It’s an industry term for a licensed attorney.  Lechtman is not licensed to practice law in the United States of America.0

Unlike the lawyers working for Squire Patton & Boggs, Jones Day’s attorneys were deeply embedded within the Trump administration among the nation’s 94 U.S. attorneys.  Jones Day partner Don McGahn was Trump’s White House counsel.  At the very highest of levels, Americans could see the Jones Day prosecutors in the Trump administration as using the job to direct a raid on the offices of a global competitor when FBI agents entered Squire Patton & Boggs’ New York to get Cohen’s server and records.

Squire Patton & Boggs has its Moscow offices located in this building at 4 Romanov pereulok.

11 Jones Day former partners were appointed U.S. Attorneys by Trump.  That’s even in Northeast Ohio where former Jones Day partner obstructed the enforcement of the three espionage-busting laws with his police blotter-like “gun” pursuit of FBI-created fake terrorists for the past four years.

The difference between the U.S. Attorneys elsewhere in contrast to Ohio is that a team of career USDOJ bureaucrats, focused on investigating Russian collusion over the past nearly four years, have now developed a body of knowledge and conclusions.  From my perspective, having followed the law firms East Cleveland resident John D. Rockefeller employed to handle his business when he was the world’s first billionaire in 1904 living in the city I once led as mayor, I see Jones Days’ abrupt departure from Moscow as their possessing “what’s coming next” knowledge.

Wondering if the Vladimir Lechtman of Jones Day is the same Vladimir Lechtman who posted this video of a Russian “state funeral” 7 months ago? They’re still carrying around Communist Party leader Josef Stalin’s picture.

Dan Boente held the job of the FBI’s general counsel until he retired from the United States Department of Justice as a career administrator.  Barack Obama appointed him to lead the U.S. Attorneys office in Eastern Virginia.

At 66 Boente’s still in play as an appointee, somewhere inside the United States Department of Justice, of President-elect Joe Biden if he wants it.  What’s of note with the Jones Day Moscow office’s closing is the policy position Boente embedded within the USDOJ that the Logan Act, Espionage Act and Foreign Agents Registration Act are “good tools” as existing laws they’ll continue to use.

Eaton’s “Global Cleveland” continues Logan Act, Espionage Act and FARA violations he started in the 1950’s through ex-con Joe Cimperman

CLEVELAND, OH – Joe Cimperman is Global Cleveland’s president.   He’s also a convicted thief, indicted on 26 counts, whose vote on Cleveland city council misdirected funds intended for impoverished Cleveland neighborhoods to a non-profit that employed a girlfriend who became his wife before he resigned to lead Global Cleveland in 2016.  He also hasn’t stopped.

Cleveland Heights resident Basheer Jones in June 2020 sponsored legislation Councilman Brian Kazy seconded to pay Cimperman’s organization $125,000 in annual “dues.”  Of course Kevin Kelly violated the city’s charter to pass the ordinance as an “emergency” providing for the usual operation of a “municipal department.”

Global Cleveland is not a “municipal department” of the government of Cleveland.  There is no section of Title 7 of the Revised Code of Ohio, or any Section in Article 18 of the Constitution of Ohio, that gives “foreign relations” duties to a “municipal corporation.  It’s a misappropriation of municipal funds that should lead to a federal investigation to identify the specific line item finance director Sharon Dumas acquired the funds from; as the ordinance did not identify it or the “emergency” that affected the usual operation of a municipal department.

Cimperman has other problems … too.

A copy of a Foreign Agents Registration Act (FARA) form the law firm of Burson & Marstellar filed with the United States Department of Justice in 2018 shows a meeting with Cimperman on behalf of their foreign government client on June 29, 2017 at a “civic” dinner with Dora Pruce.  Squire Patton Boggs lawyers filed as well.   It’s a shame the law firm represents the Cuyahoga County Mayors and City Managers Association; but doesn’t advise mayors and city mangaers when they’re working for the Russian Federation or any of their foreign clients.  This is an insidious conflict of interest.  Cimperman’s council campaign committee got $500 from Squire Patton Boggs’ out of the money they were paid by 14 foreign governments.

Global Cleveland is not affiliated with the “official” Sister Cities International U.S. Senator Marsha Blackburn, Marco Rubio, Josh Hawley and Kevin Cramer announced on November 17, 2020 they want investigated.  It only uses the name.  The official 501c.3 non-profit started in 1956 by President Dwight D. Eisenhower through an Executive Order was supposed to always be under the oversight of the United States Department of State so each relationship would be supervised and in line with U.S. foreign policy interests.  Global Cleveland’s Facebook page identifies it as a “consulting agency.”

Over the years as immigrants with either no knowledge or regard for the nation’s espionage laws got elected to local offices, they used them to create unlawful “back home” relationships that resulted in unauthorized exchanges of information between individuals calling themselves Americans and a foreign government’s officials.  Councils, commissions and school boards started passing resolutions encouraging or opposing the foreign policy decisions of the Government of the United States of America; and exercising a power that was not granted to their units of government in any federal, state or local law.  Local involvement in foreign affairs are federal crimes.

Cleveland Heights city council has no legal authority to communicate with the officials of Oblast, Russia.  Russian Bernie Sanders Gitman had no legal authority to enter a “Sister Cities” relationship with the Boris Yeltsin “appointed” mayor of Yaroslavl, Russia when he served as Burlington, Vermonts mayor.  Blackburn is calling these unauthorized, unsupervised and unlawful relationships “dangerous.”

Cleveland Heights is more than 50 percent American Negro; and the majority of the city’s residents are not from any part of Communist Russia.  Had a vote of the people been taken on a Sister City relationship with any Russian city local councils have aligned with it would have failed.

Global Cleveland just held a “Sisters City Conference” hosted by the Cleveland Public Library between September 29 – October 2, 2020 that Eisenhower’s Sister Cities International had no knowledge was occurring.  On its website there’s no record of either Global Cleveland or Joe Cimperman as being affiliated with the “real” Sister Cities International.

But Cimperman along with Cleveland Public Library director Thomas Felton made contact with the officials of 14 governments for their conference.  So did members of Cleveland city council and an an employee in Mayor Frank Jackson’s administration.  None of their contacts with the officials of 14 foreign governments was “authorized by law” even if Global Cleveland’s “conference” as a “consulting agency” was under the guise of it being sanctioned by Sister Cities International.  It wasn’t.  Just the mere mention of the word “consultant” on its Facebook page would require Global Cleveland and Cimperman, as well as the “paid elected official speakers,” to register as foreign agents under the FARA.

18 U.S. Code § 219.Officers and employees acting as agents of foreign principals.  Whoever, being a public official, is or acts as an agent of a foreign principal required to register under the Foreign Agents Registration Act of 1938 or a lobbyist required to register under the Lobbying Disclosure Act of 1995 in connection with the representation of a foreign entity, as defined in section 3(6) of that Act shall be fined under this title or imprisoned for not more than two years, or both.  (b) Nothing in this section shall apply to the employment of any agent of a foreign principal as a special Government employee in any case in which the head of the employing agency certifies that such employment is required in the national interest. A copy of any certification under this paragraph shall be forwarded by the head of such agency to the Attorney General who shall cause the same to be filed with the registration statement and other documents filed by such agent, and made available for public inspection in accordance with section 6 of the Foreign Agents Registration Act of 1938, as amended.  (c) For the purpose of this section “public official” means Member of Congress, Delegate, or Resident Commissioner, either before or after he has qualified, or an officer or employee or person acting for or on behalf of the United States, or any department, agency, or branch of Government thereof, including the District of Columbia, in any official function, under or by authority of any such department, agency, or branch of Government.

Speakers included Cleveland council president Kevin Kelly, Basheer Jones and Jasmin Santana.  The website identifies speaker fees at $2500.  Section 102 of Ohio’s Revised Code restricts elected officials from accepting “anything of value” from the use of their public office.  Identifying themselves as members of council and accepting “something of value” from the same Global Cleveland they voted to pay $125,000 in dues to puts Kelly, Jones and Santana in the same trouble Cimperman had that got him 26 indictments in 2018.

Canadian Cyrus Eaton posed as an American “industrialist” here in Cleveland while operating secretly on behalf of the Nikita Krushkev and the Kremlin as a “dual” citizen. There is no such thing as “dual citizenship” in the United States Code. Once a citizen of the United States of America you “renounce” your former nation. Immigrants are supposed to assimilate and forget “home.” Eaton was a seditious traitor.

Global Cleveland is the late Canadian citizen and Communist Cyrus Eaton’s old Pugwash Conferences.  Eaton was born in Pugwash, Nova Scotia in 1883 and worked on John D. Rockefeller’s estate in East Cleveland at what is now Forest Hill Park.  Rockefeller’s Baptist pastor was Eaton’s uncle.  When he left East Cleveland for Ormond Beach, Florida, the devoutly-Protestant Rockefeller attended the American Negro Ormond Baptist Church as its “only” so-called “white” member.

Rockefeller’s affinity for the American Negro community was legendarily-loving.  Like FBI Director John Edgar Hoover the thought in the American Negro community is that he was “passing for white.”  It was the same discussions behind Presidents Andrew Jackson, Abraham Lincoln, Wilson McKinley, Warren G. Harding and Calvin Coolidge.

Every Standard Oil board member was required by Rockefeller to be Protestant, Christian and an abolitionist. I served as the city’s mayor for 4 “out of fiscal emergency” years.  Had he not funded Spelman College from East Cleveland, Rev. Martin Luther King Jr’s mother and grandmother would not have been educated at the university that bears his wife’s family’s name.  They wouldn’t have had the intellectual capacity to educate him. Rockefeller was still alive when my grandparents arrived in Cleveland around 1919 from the Carolinas.

Rockefeller owned East Ohio Gas and was building natural gas lines like those that still exist on streets like Lakefront, Holyoke and Elsinore in East Cleveland when Eaton lived with the billionaire’s family at Forest Hills in the city.  He let Eaton negotiate some of the property disputes and deeds while learning to become a pastor from his uncle.

Living with the world’s first billionaire in East Cleveland changed his perspective; so Eaton chose business instead of the ministry.  He also later chose Nikita Krushkev and Communism over President Dwight D. Eisenhower and loyalty to the Government of the United States of America and our Republic.

Eaton claimed to have been made a citizen in 1913.  All he filed with the Cleveland municipal court was a declaration of intent that expired 6 years later; and two years before all immigration filings were required by Congress to be handled by U.S. District Courts and not the local ones in 1915.

Against U.S. foreign policy, the disloyal Canadian citizen on his own began communicating with foreign leaders he invited to his home in Northeast Ohio under the guise of “cultural exchanges.”  In truth Eaton was operating domestically as an unregistered agent of Communist Russia.

Following American Negro Paul Robeson’s receipt of the Josef Stalin Award in 1953; Eaton received the Lenin Peace Prize from Krushkev in 1960 for his work between Cleveland and Canada obstructing President Dwight D. Eisenhower’s foreign policy towards the nation and Communism.  All this was in between Congress enacting the National Security Act of 1950; and the Communist Control Act of 1954.  Both outlawed Communism or any affiliation with it in this nation; but it didn’t stop Eaton like it hasn’t stopped Global Cleveland.

When he returned to Cleveland from Russia, Eaton should have been arrested for his Logan Act, Espionage Act and FARA violations.  To receive an award from the Russian government for work that enhanced that government against the U.S. government’s interests was evidence that both he and Robeson were  Logan, Espionage and National Security Act violating traitors.  Pursuant to Chapter 18 of the United States Code, Section 953 the Logan Act instructs citizens like Cimperman of the following:

Any citizen of the United States, wherever he may be, who, without authority of the United States, directly or indirectly commences or carries on any correspondence or intercourse with any foreign government or any officer or agent thereof, with intent to influence the measures or conduct of any foreign government or of any officer or agent thereof, in relation to any disputes or controversies with the United States, or to defeat the measures of the United States, shall be fined under this title or imprisoned not more than three years, or both.

This section shall not abridge the right of a citizen to apply, himself or his agent, to any foreign government or the agents thereof for redress of any injury which he may have sustained from such government or any of its agents or subjects.

Cimperman’s name appears along with that of Mayor Frank Jackson and County Executive Armond Budish on two FARA forms; but not on those that require them to report foreign agent contacts.  The “foreign agents” reported to the U.S. Department of Justice that they met with the three.  The three did not share their foreign agent meetings with the USDOJ.  Neither did Mark Naymik as a cleveland.com reporter.

Squire Patton & Boggs was representing 14 governments when they met with Jackson.  Matt Cox of Burson Marstellar met with Cimperman on June 29, 2017 as Global Cleveland’s president.  Cimperman was indicted on state charges that should have been federal in April 2018.  All were supposed to report their contacts with the foreign agents with the U.S. DOJ’s FARA division.

The City of Cleveland’s logo is attached to the Global Cleveland website.  18 U.S.C. 853, the Logan Act, did not authorize the mayor or council member of a municipal corporation to communicate with foreign officials.  Foreign affairs duties for municipal corporations is not written into any section of the Revised Code of Ohio under Title 7.  The use of a “municipal public office” to engage in foreign affairs reserved for Congress should result in not only a “stateu audit finding,” but criminal prosecution for exceeding the authority of the office and a suit to recapture the misappropriated public funds.

The non-profit’s mission makes it ineligible in every way to receive a dime in federal block grant or municipal funds funds; particularly since Cleveland council has unlawfully designated the city a “sanctuary” for illegal immigration Cimperman’s Global Cleveland criminally-supports in obstruction of the nation’s immigration laws.  Jackson and Cleveland city council violate federal laws when they spend municipal or federal block grant funds with Global Cleveland in obstruction of the local enforcement of the nation’s federal immigration laws and foreign policy.  Jackson and Kelly were elected to make sure the trash was collected.  No sane American citizen would elect either of them to handle foreign affairs.

Just this past September 29th through October 2, 2020, Global Cleveland hosted a global seminar or what it claimed was a “Sister Cities Conference 2020.”  The event was described on Global Cleveland’s website as follows:

A 3-day interactive event bringing together representatives from 20+ sister cities to discuss their partnership goals, successes, and aspirations to cross-pollinate ideas and forge a connection.  This event is free and open to all community members interested in learning more about Cleveland’s international connections from a ground-level perspective.  We will have representatives from our Sister Cities engaging with community members, business leaders, students, and civic leaders. The host committee of the Sister Cities Conference will be on hand to speak about the city-city relationship, past accomplishments, and goals for the future.  Benefits of a Sister City: Direct contact with local businesses, civic leaders, and educational institutions around the world. Increased cooperation, respect, and hence prosperity for both cities and their people.

Global Cleveland identified the following as keynote speakers:

Director Felton Thomas, Cleveland Public Library Director;  Ambassador Daniel Mulhall, Ambassador of Ireland to the United States;  Council President Kevin Kelley, Cleveland City Council President;  Ted Carter, Cuyahoga County’s Chief Economic Development and Business Officer;  Nizar Zein, Cleveland Clinic Director of Global Patient Services;  Ronn Richard, Cleveland Foundation President;  Fernando Gonzalez Saiffe, Consul General of Mexico in Chicago;  Director-General Eric Huang, Taipei Economic and Cultural Office in Chicago.

On Wednesday, September 20, 2020 a panel of “international mayors” joined a conversation.  Jackson did not participate.  An employee, Alex Lackey, whose title is claimed to be the Government and International Affairs Manager, filled in  for Cleveland’s “mayor.”

City of Cleveland Government and International Affairs Manager, Alex Lackey;  Deputy Mayor Mr. Dejan Crnek- Ljubljana, Slovenia;  Chief Bayo Oyero, Ibadan, Nigeria;  Mayor Jackie Levy, Beit She’an, Israel;  Mayor Yoram Karin-Valley of the Springs, Israel;  Managing Director of International Relations, Leonardo De Marzo- Vicenza, Italy;  Mayor Vytautas Grubliauskas- Klaipeda, Lithuania;  Mayor, Pál Veres – Miskolc, Hungary

Who was not in attendance in the conference was anyone from the United States Department of State.  That federal government agency’s logo is not on the Global Cleveland website; and its “sister cities” program is not identified on the United States Department of State’s website was one that is “authorized” by law.

Sisters Cities International officials had no knowledge of this event and did not promote it. Global Cleveland operates a consulting agency under the guise of the organization being affiliated with Sisters Cities International.

The U.S. Department of Housing & Urban Development’s Inspector General, as well as Ohio’s Auditor of State, should have long ago investigated Jackson and council’s misappropriation of federal block grant funds equally to members of council in wards ineligible to receive it.  Cleveland members of council are all following the same “outside the federal law” distribution of block grant funds to who they want, instead of obeying the city’s “grant management agreement with HUD and federal laws.

The late reporter Benjamin Wells in an October 3, 1971 story for the New York Times wrote about “Soviet” espionage and identified the United States of America as a main target.   Wells’ story identified two types of Soviet immigrants living in the United States of America.

According to U.S. Immigration records, Wells reported that only 1380 “legal” Soviets or Russians were residents of the nation as a result of the Chinese Exclusion Act of 1894 restrictions codified in the 1921 Emergency Immigration Quota Act; and again in the 1929 federal law President Calvin Coolidge signed under the same name.  The rest, Wells wrote, were “illegal.”  The majority of the illegal Russians he described as “deep cover spies” who were “concentrated in New York.”  Today’s U.S. Russian or Soviet population exceeds 6 million.

The “legals” allowed in were the “Albert Einstein” exceptionals.  Not the Ratner’s, Bloomberg’s, Klobuchar’s, Epstein’s, Pritikin’s, Schiffs, Nadler’s, Ginsburg’s and others who claimed their ancestors arrived here poor “looking for opportunities.”  America’s immigration laws have never “welcomed” poor, uneducated or average-educated immigrants.

This is the form individuals making contacts with foreign agents are required to submit to the USDOJ. The foreign agents have identified in their reports the contacts who should have completed this one. This writer served at the CIA’s Air America base at Udorn Thailand during the end of the Vietnam War. We were instructed on how to make and report contacts with “foreign nationals.” It’s that “name, rank and serial number” thing when captured. The “only” conversations American citizens can have with a foreign government’s officials, anywhere they may be, is those authorized by the Government of the United States of America. A city council is not the Government of “the” United States of America. Neither is a non-reading mayor. When Blaine Griffn and Jasmin Santana returned from Israel meeting with foreign government officials, they should have submitted this form with the USDOJ’s FARA unit. Cleveland Foundation CEO Ron Richards was in the CIA at the same base. He knows.

The Chinese Exclusion Act limited immigration from “all” of Eastern Europe, not just Russia, to no more than 73 immigrants per year.  The idea of one Ratner entering the nation and arranging for his 8 brothers to arrive here in 1920, all at one time, is evidence of organized crime.  Wells wrote the following in 1971.

The main concentrations of Soviet citizens officially in the United States are said to include 400 to 500 in the Soviet Embassy and its branches here; 800 to 900 in the New York area, including 120 to 150 at the Soviet Mission to the United Nations; 150 to 160 working as international civil servants in the United Nations; 10 to 20 at the Amtorg trade delegation; 10 to 20 working jointly for Aeroflot and Intourist plus 10 to 20 correspondents for Tass and other Soviet news agencies.

There are also hundreds each year who come in and out on temporary duty to attend trade, cultural and scientific conferences,” said an American security expert. “Many are known, identified, K.G.B. or G.R.U. officers.”

Currently the legal Soviet presence in the United States comprises 1,380 men, women and children. About half of the men are considered by the security services to be agents of the K.G.B. or G.R.U., the military intelligence. Many Soviet wives here are also believed to work for one of the services.

President Donald Trump’s administration misdirected attention away from Russia and focused on China; it’s next door neighbor.  Senator Washburns’ concerns about China in her letter to the member mayors of the U.S. Conference of Mayors in October 2020 echoes the same either way for both Communist nations.

“Sister-city partnerships may be Beijing’s newest political weapon. Across the globe, China has exploited these relationships, which are ostensibly intended to promote cultural exchange, to achieve geostrategic goals,” said Senator Blackburn. “It is imperative we shed light on these partnerships to determine whether they leave American communities vulnerable to foreign espionage and ideological coercion.”

“The Chinese Communist Party wants to spread its influence wherever it can. Now there is reason to believe Beijing is using partnerships between local governments in the United States and China to spread lies, steal ideas, and gather information it can use against Americans. The Sister City Transparency Act shines a light on this threat and ensures we have the information we need to protect our communities from the Chinese government’s spies and propagandists,” said Senator Hawley.

“Communist China regularly exploits its sister-city partnerships around the world to aggressively advance its own agenda,” said Senator Cramer. “Our bill would give us a better understanding of China’s reach into the United States and allow us to address that accordingly.”

“The Chinese government and Communist Party has a history of exploiting cultural and economic partnerships to conduct malign activities, and it’s clear that opaque, sister-city partnerships deserve increased scrutiny,” Senator Rubio said. “We must do more to better understand, and then counter, Chinese influence operations at the state and local level, which are often conducted under the benign auspices of sister city relationships. I am proud to join Senator Blackburn on this legislation, and I hope our colleagues will support our efforts to provide greater transparency and diligence in preventing the CCP’s efforts to exert sharp power and conduct influence operations in the U.S.”

According the yet-to-be-written language of Washburn, Hawley, Rubio and Cramer’s proposed admendments, the Sister City Transparency Act would literally shut down Global Cleveland’s “loose” operation as a consulting agency with tight oversight and monitoring; and safeguards to prevent academic and industrial espionage.  Global Cleveland’s current convict-led operation looks like an international espionage ring that’s setting up local elected and appointed officials too ignorant to read the nation’s laws in a Democratic run city for one of the biggest international federal spy ring bust in the history of the world.

The foreign agents as I’ve demonstrated in their filings have identified their contacts with the USDOJ’s FARA unit.  The USDOJ knows the contacts who had filing requirements after the meeting.  Federal prosecutors can identify in the filings the names of the contacts who did not report to them on the required form the nature of the meeting.  It’s not often what you do in politics that gets you busted.  It’s what you don’t do that you’re required to do that gets you busted.

Skip to toolbar